Piret的个人主页 - 老虎社区

Piret

Piret

暂无个人介绍

IP属地：未知

100关注

6粉丝

0主题

0勋章

2021-12-29

Okay

抱歉，原内容已删除

2021-12-19

Okay

Wall Street ends down after mostly negative week

2021-12-17

Okay

Intel: Mobileye IPO Could Be A Masterstroke

2021-12-15

Okay

2 Warren Buffett Dividend Stocks to Buy Right Now

2021-12-14

Ok

Veru jumped over 13% in premarket trading as it announced FDA approval of ENTADFI

2021-12-11

Okay

Hedge Funds Ensnared in Expansive DOJ Probe Into Short Selling

2021-12-08

Okay

Toplines Before US Market Open on Tuesday

2021-12-07

Okay

10 Biggest Price Target Changes For Monday

2021-11-30

Ok

抱歉，原内容已删除

2021-11-22

Like plsThank you

Here's what history says about stock-market performance during the Thanksgiving week

2021-11-22

Like pls, thank you

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4100520219096230","uuid":"4100520219096230","gmtCreate":1637419867374,"gmtModify":1637620471486,"name":"Piret","pinyin":"piret","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/32af1c6079ca483ba4808b65db688b5e","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":6,"headSize":100,"tweetSize":11,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"80.51%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":696763788,"gmtCreate":1640772134268,"gmtModify":1640772134419,"author":{"id":"4100520219096230","authorId":"4100520219096230","name":"Piret","avatar":"https://static.tigerbbs.com/32af1c6079ca483ba4808b65db688b5e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100520219096230","idStr":"4100520219096230"},"themes":[],"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696763788","repostId":"1147732268","repostType":4,"isVote":1,"tweetType":1,"viewCount":993,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699451526,"gmtCreate":1639880886508,"gmtModify":1639880886601,"author":{"id":"4100520219096230","authorId":"4100520219096230","name":"Piret","avatar":"https://static.tigerbbs.com/32af1c6079ca483ba4808b65db688b5e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100520219096230","idStr":"4100520219096230"},"themes":[],"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699451526","repostId":"1116106959","repostType":4,"repost":{"id":"1116106959","kind":"news","pubTimestamp":1639785552,"share":"https://www.laohu8.com/m/news/1116106959?lang=&edition=full","pubTime":"2021-12-18 07:59","market":"us","language":"en","title":"Wall Street ends down after mostly negative week","url":"https://stock-news.laohu8.com/highlight/detail?id=1116106959","media":"Reuters","summary":" - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.All three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.Nvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&P 500 and Nasdaq.The S","content":"<p>(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.</p>\n<p>All three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.</p>\n<p>Nvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&amp;P 500 and Nasdaq.</p>\n<p>The S&amp;P 500 growth index lost 0.7% and the value index declined 1.4%.</p>\n<p>All of the 11 major S&amp;P 500 sector indexes fell, with financials leading the way down with a 2.3% drop. Energy lost 2.2%.</p>\n<p>Adding to uncertainty, Pfizer said on Friday the pandemic could extend through next year. European countries geared up for further travel and social restrictions and a study warned that the rapidly spreading Omicron coronavirus variant was five times more likely to reinfect people than its predecessor, Delta.</p>\n<p>Traders also pointed to year-end tax selling and the simultaneous expiration of stock options, stock index futures and index options contracts - known as triple witching - as potential causes for volatility.</p>\n<p>\"It's a big options expiration day,\" said Joe Saluzzi, co-manager of trading at Themis Trading in Chatham, New Jersey. \"And now you draw on top of that some Omicron, and you've got volatility, and I think it creates a lot of uncertainty amongst investors. Where are you going to position for the end of the year?\"</p>\n<p>Heavyweight growth stocks including Nvidia and Microsoft have outperformed the broader market in 2021, while the Philadelphia SE Semiconductor index has surged about 35%. The benchmark S&amp;P 500 index gained around 23% in the same period.</p>\n<p>In Friday's session, the Dow Jones Industrial Average fell 1.48% to end at 35,365.44 points, while the S&amp;P 500 lost 1.03% to 4,620.64.</p>\n<p>The Nasdaq Composite dropped 0.07% to 15,169.68.</p>\n<p>On a positive note, the small-cap Russell 2000 index rallied 1% after having fallen more than 10% from a record high in early November.</p>\n<p>With options expiring, volume on U.S. exchanges jumped to 16.6 billion shares, far above the 11.9 billion average over the last 20 trading days.</p>\n<p>For the week, the S&amp;P 500 fell 1.9%, the Dow lost 1.7% and the Nasdaq declined 2.9%.</p>\n<p>In Friday's session, Oracle tumbled 6.4% after the Wall Street Journal reported the enterprise software maker is in talks to buy electronic medical records company Cerner in a deal that could be valued at $30 billion. Shares of Cerner surged 12.9%.</p>\n<p>FedEx Corp rose almost 5% after the delivery firm reinstated its original fiscal 2022 forecast on Thursday, even as persistent labor woes chipped away profits.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.50-to-1 ratio; on Nasdaq, a 1.16-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 22 new 52-week highs and seven new lows; the Nasdaq Composite recorded 28 new highs and 341 new lows.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street ends down after mostly negative week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street ends down after mostly negative week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-18 07:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-...</p>\n\n<a href=\"https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"source_url":"https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116106959","content_text":"(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.\nAll three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.\nNvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&P 500 and Nasdaq.\nThe S&P 500 growth index lost 0.7% and the value index declined 1.4%.\nAll of the 11 major S&P 500 sector indexes fell, with financials leading the way down with a 2.3% drop. Energy lost 2.2%.\nAdding to uncertainty, Pfizer said on Friday the pandemic could extend through next year. European countries geared up for further travel and social restrictions and a study warned that the rapidly spreading Omicron coronavirus variant was five times more likely to reinfect people than its predecessor, Delta.\nTraders also pointed to year-end tax selling and the simultaneous expiration of stock options, stock index futures and index options contracts - known as triple witching - as potential causes for volatility.\n\"It's a big options expiration day,\" said Joe Saluzzi, co-manager of trading at Themis Trading in Chatham, New Jersey. \"And now you draw on top of that some Omicron, and you've got volatility, and I think it creates a lot of uncertainty amongst investors. Where are you going to position for the end of the year?\"\nHeavyweight growth stocks including Nvidia and Microsoft have outperformed the broader market in 2021, while the Philadelphia SE Semiconductor index has surged about 35%. The benchmark S&P 500 index gained around 23% in the same period.\nIn Friday's session, the Dow Jones Industrial Average fell 1.48% to end at 35,365.44 points, while the S&P 500 lost 1.03% to 4,620.64.\nThe Nasdaq Composite dropped 0.07% to 15,169.68.\nOn a positive note, the small-cap Russell 2000 index rallied 1% after having fallen more than 10% from a record high in early November.\nWith options expiring, volume on U.S. exchanges jumped to 16.6 billion shares, far above the 11.9 billion average over the last 20 trading days.\nFor the week, the S&P 500 fell 1.9%, the Dow lost 1.7% and the Nasdaq declined 2.9%.\nIn Friday's session, Oracle tumbled 6.4% after the Wall Street Journal reported the enterprise software maker is in talks to buy electronic medical records company Cerner in a deal that could be valued at $30 billion. Shares of Cerner surged 12.9%.\nFedEx Corp rose almost 5% after the delivery firm reinstated its original fiscal 2022 forecast on Thursday, even as persistent labor woes chipped away profits.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.50-to-1 ratio; on Nasdaq, a 1.16-to-1 ratio favored advancers.\nThe S&P 500 posted 22 new 52-week highs and seven new lows; the Nasdaq Composite recorded 28 new highs and 341 new lows.","news_type":1},"isVote":1,"tweetType":1,"viewCount":893,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699006758,"gmtCreate":1639716801585,"gmtModify":1639716801682,"author":{"id":"4100520219096230","authorId":"4100520219096230","name":"Piret","avatar":"https://static.tigerbbs.com/32af1c6079ca483ba4808b65db688b5e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100520219096230","idStr":"4100520219096230"},"themes":[],"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699006758","repostId":"1169026598","repostType":4,"repost":{"id":"1169026598","kind":"news","pubTimestamp":1639698567,"share":"https://www.laohu8.com/m/news/1169026598?lang=&edition=full","pubTime":"2021-12-17 07:49","market":"us","language":"en","title":"Intel: Mobileye IPO Could Be A Masterstroke","url":"https://stock-news.laohu8.com/highlight/detail?id=1169026598","media":"seekingalpha","summary":"Summary\n\nIntel is spinning off Mobileye via an IPO in mid 2022 to raise capital for its ambitious gr","content":"<p><b>Summary</b></p>\n<ul>\n <li>Intel is spinning off Mobileye via an IPO in mid 2022 to raise capital for its ambitious growth plans. In this note, we will discuss the logic of this transaction.</li>\n <li>Mobileye is one of the leading players in autonomous vehicle technology, which means it should command a much higher multiple than Intel.</li>\n <li>At ~9x Price-to-FCF, Intel is massively undervalued, and as such Mobileye's valuation is suppressed. The IPO is likely to act as a significant value unlocking event for Intel.</li>\n <li>According to my analysis, Mobileye could quite easily fetch a valuation of $50-100B in the current market environment. Hence, Intel could raise a significant sum by selling just a minor stake.</li>\n <li>Even after the IPO, Intel will continue to control Mobileye with a majority stake, and Intel's CEO, Pat Gelsinger, will be shaping Mobileye's future as the Chairman of its Board. Hence, Intel is getting the best of both worlds with this deal. I rate Intel a strong buy at $50.</li>\n <li>Looking for a portfolio of ideas like this one? Members of Beating the Market get exclusive access to our model portfolio.</li>\n</ul>\n<p><b>Introduction</b></p>\n<p>Despite the astounding rally in chip stocks over the last 18-24 months, Intel's (NASDAQ:INTC) valuation (~12x P/FCF) continues to remain depressed. The semiconductor supply shortage is showing no signs of abating, with Intel selling all that it could make. In 2021, Intel is set to generate record revenues and operating cash flows. Although Intel is facing margin pressures due to heightened competition, its business fundamentals remain strong. Intel's balance sheet and free cash flow generation are robust. An inflationary environment is supposed to be supportive of cash flow machines like Intel. Hence, the weak price action in Intel is puzzling (even after considering Intel's manufacturing woes over the last few years).</p>\n<p>In today's note, we will focus our discussion on Intel's upcoming spinoff Mobileye, which is likely to act as a value unlocking catalyst for this chip giant.</p>\n<p>Let's begin our analysis by deciphering the logic behind an IPO for Mobileye.</p>\n<p><b>Understanding The Motivation Behind Intel's Mobileye Spinoff</b></p>\n<p>Soon after rejoining Intel as CEO, Pat Gelsinger outlined an aggressive hybrid-sourcing and foundry plan to take the semiconductor giant back to its past glory (after some woeful execution from previous management). On paper, Pat's strategy is very simple. Intel will outsource next-gen chip manufacturing to foundries like TSMC (NYSE:TSM), which would enable them to compete against rivals like AMD (NASDAQ:AMD) and Nvidia (NASDAQ:NVDA). While Intel is working toward fixing its manufacturing woes and regaining the technological lead at the node level, the company also is opening up its manufacturing plants in the Western Hemisphere for other companies (i.e., entering the foundry business).</p>\n<p></p>\n<p>The semiconductor industry is undergoing a painful supply crisis that has had far-reaching impacts across multiple industries. With the EV revolution, the demand for automotive chips is set to explode higher. Hence, the chip shortage could last for years and years. Only a handful of companies can solve this crisis, and Intel is probably the only company that could help abate this semiconductor shortage in the Western Hemisphere.</p>\n<p>Pat Gelsinger has put forward an aggressive growth plan for Intel, which could see the company growing at ~10-12% CAGR from 2023-2027. However, Pat's plan is highly capital intensive, and so Intel needs more capital.</p>\n<p><img src=\"https://static.tigerbbs.com/469130405b455b41aba450a41af1ccd1\" tg-width=\"1122\" tg-height=\"551\" referrerpolicy=\"no-referrer\"></p>\n<p>Intel is set to enter a heavy capex-spending cycle with plans to increase capex for 2022 to ~$25B-$28B. With Intel's stock trading close to record low valuation (by P/FCF) from the past 10 years, raising capital through fresh equity issuance would be highly dilutionary for Intel's shareholders. Intel is one of the most-hated stocks on Wall Street, and the management certainly is not interested in alienating more of its investor base. Hence, a capital raise through equity is ruled out.</p>\n<p>Another way to raise capital would be through debt issuance, and Intel's balance sheet and free cash flow generation are strong enough to allow for more debt. However, Intel's margins are set to come under pressure due to a potential price war with the likes of AMD, and with increased CAPEX-spending, Intel's free cash flows may suffer too in the near term. Hence, Intel's management could be unwilling to raise more capital via debt (which already stands at ~$40B).</p>\n<p>Asset monetization was probably the only viable alternative for raising capital to fund Intel's growth plan. And if we look at Intel's business, Mobileye is probably the most under-appreciated asset buried under a steep conglomerate discount. Mobileye is a category-leading business in autonomous driving (one of the hottest spaces in the market), and it would undoubtedly command a much higher trading multiple in the current market environment than what Intel paid for it back in 2017. Hence, the Mobileye spinoff is a very sound and logical decision from Intel's management.</p>\n<p><b>Pat Says Mobileye Is Comparable To Tesla! Is It Though?</b></p>\n<p>In 2017, Intel acquired Mobileye for an eye-watering sum of ~$15.3B. Since this acquisition, Mobileye has delivered significant revenue growth, achieved numerous technical innovations, and invested capital toward solving the most critical problems in the scaled deployment of autonomous driving technology. Unlike most IPOs, Mobileye is already a highly-profitable company. Hence, Intel could get a big return on its investment by selling a minority stake in Mobileye.</p>\n<p>In the last 12 months, Mobileye has generated revenues of $1.36B, with operating profits coming in at $471M (operating margin of ~35%). Also, Mobileye achieved the milestone of delivering its 100 millionth EyeQ SOC, unveiled its production robotaxi (network coming live in 2022) and won 41 new ADAS and full self-driving programs with 30 legacy automakers. In a nutshell, Mobileye has taken tremendous strides both from a technical and financial standpoint.</p>\n<p>Since Mobileye has always operated as an independent subsidiary within Intel, the separation won't be hard. The strategic partnership with Intel will remain in place, and higher visibility should enable Mobileye to win more partners across the globe. With its robotaxi network set to go live in 2022, Mobileye is probably going to be the first to market in L3/L4 AV technology.</p>\n<p>Mobileye is truly at an inflection point, and its future looks as bright as ever. Some critics would say that Intel is selling its future to chase the past. However, we must acknowledge the realities around us. The hype around autonomous driving and EVs has never been higher, and Mobileye's spectacular growth story is buried under Intel's umbrella. By bringing Mobileye to the public markets as a standalone entity, Intel is likely to receive a cash boost (at a rich trading multiple), whilst it will also maintain its majority stake (control) in the company.</p>\n<p>Although Pat compared Mobileye to Tesla (NASDAQ:TSLA) due to its AV technology (and future Robotaxi business), I think it's more comparable to Nvidia. For the purpose of this note, we shall create a guesstimate for Mobileye's valuation using trading multiples for both Tesla and Nvidia. Due to its relatively small size, I would expect Mobileye to command a higher multiple than these companies.</p>\n<p>Looking through the lens of relative valuation, Mobileye's IPO could be valued anywhere in the range of ~$50B to $70B. However, let us also determine Mobileye's absolute valuation using its financials.</p>\n<p><b>Estimating Mobileye's Fair Value</b></p>\n<p>To determine Mobileye's fair value, we will employ our proprietary valuation model. Here's what it entails:</p>\n<ul>\n <li>In step 1, we use a traditional DCF model with free cash flow discounted by our (shareholders) cost of capital.</li>\n <li></li>\n <li>In step 2, the model accounts for the effects of the change in shares outstanding (buybacks/dilutions).</li>\n <li></li>\n <li>In step 3, we normalize valuation for future growth prospects at the end of the ten years. Then, we arrive at a CAGR using today's share price and the projected share price at the end of 10 years. If this beats the market by enough of a margin, we invest. If not, we wait for a better entry point.</li>\n <li></li>\n <li>In step 4, the model accounts for dividends.</li>\n</ul>\n<p><b>Assumptions:</b></p>\n<p>Mobileye is a rapidly-growing, highly-profitable business. With a massive TAM and leading ADAS &amp; Autonomous Vehicle [AV] technology, Mobileye is set to ride an enormous secular growth trend as the shift to autonomous-driving EVs accelerates over the 2020s. Hence, a 10-year CAGR growth rate of 25% could be highly conservative. As the MoovitAV robotaxi network grows, Mobileye's margins are likely to head higher. Therefore, Mobileye's FCF margin could quite comfortably hover at more than 30% when the business matures, and growth slows down (not going to happen for another decade or two).</p>\n<p>As you can see, Mobileye is worth ~$15 per share or ~$60B market cap. The assumptions utilized in this valuation exercise are conservative, which means Mobileye could be worth even more than $60B.</p>\n<p>If Mobileye's 10-year CAGR revenue growth rate were to be in the 30%-50% range (instead of our estimate of 25%), Mobileye's fair value would come out to be ~$88B to ~$340B. At a $1T valuation, Tesla's implied 10-year CAGR revenue growth rate is ~50%. Since Mobileye is growing from a much smaller base, and considering the fact that it could become the industry standard for AV technology (by leveraging existing relationships with legacy automakers like Ford, BMW, and many others), I would imagine Mobileye has a better chance of delivering such hyper-growth than Tesla.</p>\n<p>Even after the spinoff of Mobileye, Intel would generate revenues of ~$73B in 2022 with virtually zero impact on its cash flow generation. Although Intel will lose one of its key assets in this transaction (not really, as Intel will still control Mobileye through a majority stake), the proceeds will help Intel's management execute its ambitious growth plans. Using conservative estimates, Intel (minus Mobileye) is still worth ~$70 per share (~$280B market cap) (this valuation exercise is available in my previous articles on Intel). Therefore, the Mobileye spinoff is very likely to unlock hidden value for Intel's shareholders.</p>\n<p><b>Concluding Thoughts</b></p>\n<p>With Intel's market cap hovering at just about $200B, raising capital through stock issuance is not viable. Although Intel's balance sheet and free cash flow generation remain robust, the company is entering a heavy capex-spending cycle, which makes an additional debt raise troublesome. Mobileye is one of the faster-growing business lines at Intel. However, selling a small piece of it could yield a massive sum for Intel, which could be utilized toward Pat Gelsinger's ambitious growth plan for the company. According to my analysis, Mobileye could fetch a valuation of $50B-$100B in the current market environment, and I think Intel will end up raising ~$10B-$15B from the Mobileye IPO while retaining control of the company. I like this move from Intel's management as I can see significant value unlocking from this spinoff.</p>\n<p>Intel is a deeply undervalued cash cow that pays out a healthy, growing dividend. With the Mobileye IPO set to unlock some of Intel's hidden value, I expect to see big capital appreciation in Intel over the next 12-24 months. Therefore, I continue to rate Intel a strong buy at $50.</p>\n<p>Key Takeaway: I rate Intel a strong buy at $50.</p>\n<p>Thanks for reading, and happy investing. Please share your thoughts, concerns, and/or questions in the comments section below.</p>","source":"lsy1638401102509","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel: Mobileye IPO Could Be A Masterstroke</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel: Mobileye IPO Could Be A Masterstroke\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-17 07:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4474906-intel-mobileye-ipo-masterstroke><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summary\n\nIntel is spinning off Mobileye via an IPO in mid 2022 to raise capital for its ambitious growth plans. In this note, we will discuss the logic of this transaction.\nMobileye is one of the ...</p>\n\n<a href=\"https://seekingalpha.com/article/4474906-intel-mobileye-ipo-masterstroke\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INTC":"英特尔"},"source_url":"https://seekingalpha.com/article/4474906-intel-mobileye-ipo-masterstroke","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1169026598","content_text":"Summary\n\nIntel is spinning off Mobileye via an IPO in mid 2022 to raise capital for its ambitious growth plans. In this note, we will discuss the logic of this transaction.\nMobileye is one of the leading players in autonomous vehicle technology, which means it should command a much higher multiple than Intel.\nAt ~9x Price-to-FCF, Intel is massively undervalued, and as such Mobileye's valuation is suppressed. The IPO is likely to act as a significant value unlocking event for Intel.\nAccording to my analysis, Mobileye could quite easily fetch a valuation of $50-100B in the current market environment. Hence, Intel could raise a significant sum by selling just a minor stake.\nEven after the IPO, Intel will continue to control Mobileye with a majority stake, and Intel's CEO, Pat Gelsinger, will be shaping Mobileye's future as the Chairman of its Board. Hence, Intel is getting the best of both worlds with this deal. I rate Intel a strong buy at $50.\nLooking for a portfolio of ideas like this one? Members of Beating the Market get exclusive access to our model portfolio.\n\nIntroduction\nDespite the astounding rally in chip stocks over the last 18-24 months, Intel's (NASDAQ:INTC) valuation (~12x P/FCF) continues to remain depressed. The semiconductor supply shortage is showing no signs of abating, with Intel selling all that it could make. In 2021, Intel is set to generate record revenues and operating cash flows. Although Intel is facing margin pressures due to heightened competition, its business fundamentals remain strong. Intel's balance sheet and free cash flow generation are robust. An inflationary environment is supposed to be supportive of cash flow machines like Intel. Hence, the weak price action in Intel is puzzling (even after considering Intel's manufacturing woes over the last few years).\nIn today's note, we will focus our discussion on Intel's upcoming spinoff Mobileye, which is likely to act as a value unlocking catalyst for this chip giant.\nLet's begin our analysis by deciphering the logic behind an IPO for Mobileye.\nUnderstanding The Motivation Behind Intel's Mobileye Spinoff\nSoon after rejoining Intel as CEO, Pat Gelsinger outlined an aggressive hybrid-sourcing and foundry plan to take the semiconductor giant back to its past glory (after some woeful execution from previous management). On paper, Pat's strategy is very simple. Intel will outsource next-gen chip manufacturing to foundries like TSMC (NYSE:TSM), which would enable them to compete against rivals like AMD (NASDAQ:AMD) and Nvidia (NASDAQ:NVDA). While Intel is working toward fixing its manufacturing woes and regaining the technological lead at the node level, the company also is opening up its manufacturing plants in the Western Hemisphere for other companies (i.e., entering the foundry business).\n\nThe semiconductor industry is undergoing a painful supply crisis that has had far-reaching impacts across multiple industries. With the EV revolution, the demand for automotive chips is set to explode higher. Hence, the chip shortage could last for years and years. Only a handful of companies can solve this crisis, and Intel is probably the only company that could help abate this semiconductor shortage in the Western Hemisphere.\nPat Gelsinger has put forward an aggressive growth plan for Intel, which could see the company growing at ~10-12% CAGR from 2023-2027. However, Pat's plan is highly capital intensive, and so Intel needs more capital.\n\nIntel is set to enter a heavy capex-spending cycle with plans to increase capex for 2022 to ~$25B-$28B. With Intel's stock trading close to record low valuation (by P/FCF) from the past 10 years, raising capital through fresh equity issuance would be highly dilutionary for Intel's shareholders. Intel is one of the most-hated stocks on Wall Street, and the management certainly is not interested in alienating more of its investor base. Hence, a capital raise through equity is ruled out.\nAnother way to raise capital would be through debt issuance, and Intel's balance sheet and free cash flow generation are strong enough to allow for more debt. However, Intel's margins are set to come under pressure due to a potential price war with the likes of AMD, and with increased CAPEX-spending, Intel's free cash flows may suffer too in the near term. Hence, Intel's management could be unwilling to raise more capital via debt (which already stands at ~$40B).\nAsset monetization was probably the only viable alternative for raising capital to fund Intel's growth plan. And if we look at Intel's business, Mobileye is probably the most under-appreciated asset buried under a steep conglomerate discount. Mobileye is a category-leading business in autonomous driving (one of the hottest spaces in the market), and it would undoubtedly command a much higher trading multiple in the current market environment than what Intel paid for it back in 2017. Hence, the Mobileye spinoff is a very sound and logical decision from Intel's management.\nPat Says Mobileye Is Comparable To Tesla! Is It Though?\nIn 2017, Intel acquired Mobileye for an eye-watering sum of ~$15.3B. Since this acquisition, Mobileye has delivered significant revenue growth, achieved numerous technical innovations, and invested capital toward solving the most critical problems in the scaled deployment of autonomous driving technology. Unlike most IPOs, Mobileye is already a highly-profitable company. Hence, Intel could get a big return on its investment by selling a minority stake in Mobileye.\nIn the last 12 months, Mobileye has generated revenues of $1.36B, with operating profits coming in at $471M (operating margin of ~35%). Also, Mobileye achieved the milestone of delivering its 100 millionth EyeQ SOC, unveiled its production robotaxi (network coming live in 2022) and won 41 new ADAS and full self-driving programs with 30 legacy automakers. In a nutshell, Mobileye has taken tremendous strides both from a technical and financial standpoint.\nSince Mobileye has always operated as an independent subsidiary within Intel, the separation won't be hard. The strategic partnership with Intel will remain in place, and higher visibility should enable Mobileye to win more partners across the globe. With its robotaxi network set to go live in 2022, Mobileye is probably going to be the first to market in L3/L4 AV technology.\nMobileye is truly at an inflection point, and its future looks as bright as ever. Some critics would say that Intel is selling its future to chase the past. However, we must acknowledge the realities around us. The hype around autonomous driving and EVs has never been higher, and Mobileye's spectacular growth story is buried under Intel's umbrella. By bringing Mobileye to the public markets as a standalone entity, Intel is likely to receive a cash boost (at a rich trading multiple), whilst it will also maintain its majority stake (control) in the company.\nAlthough Pat compared Mobileye to Tesla (NASDAQ:TSLA) due to its AV technology (and future Robotaxi business), I think it's more comparable to Nvidia. For the purpose of this note, we shall create a guesstimate for Mobileye's valuation using trading multiples for both Tesla and Nvidia. Due to its relatively small size, I would expect Mobileye to command a higher multiple than these companies.\nLooking through the lens of relative valuation, Mobileye's IPO could be valued anywhere in the range of ~$50B to $70B. However, let us also determine Mobileye's absolute valuation using its financials.\nEstimating Mobileye's Fair Value\nTo determine Mobileye's fair value, we will employ our proprietary valuation model. Here's what it entails:\n\nIn step 1, we use a traditional DCF model with free cash flow discounted by our (shareholders) cost of capital.\n\nIn step 2, the model accounts for the effects of the change in shares outstanding (buybacks/dilutions).\n\nIn step 3, we normalize valuation for future growth prospects at the end of the ten years. Then, we arrive at a CAGR using today's share price and the projected share price at the end of 10 years. If this beats the market by enough of a margin, we invest. If not, we wait for a better entry point.\n\nIn step 4, the model accounts for dividends.\n\nAssumptions:\nMobileye is a rapidly-growing, highly-profitable business. With a massive TAM and leading ADAS & Autonomous Vehicle [AV] technology, Mobileye is set to ride an enormous secular growth trend as the shift to autonomous-driving EVs accelerates over the 2020s. Hence, a 10-year CAGR growth rate of 25% could be highly conservative. As the MoovitAV robotaxi network grows, Mobileye's margins are likely to head higher. Therefore, Mobileye's FCF margin could quite comfortably hover at more than 30% when the business matures, and growth slows down (not going to happen for another decade or two).\nAs you can see, Mobileye is worth ~$15 per share or ~$60B market cap. The assumptions utilized in this valuation exercise are conservative, which means Mobileye could be worth even more than $60B.\nIf Mobileye's 10-year CAGR revenue growth rate were to be in the 30%-50% range (instead of our estimate of 25%), Mobileye's fair value would come out to be ~$88B to ~$340B. At a $1T valuation, Tesla's implied 10-year CAGR revenue growth rate is ~50%. Since Mobileye is growing from a much smaller base, and considering the fact that it could become the industry standard for AV technology (by leveraging existing relationships with legacy automakers like Ford, BMW, and many others), I would imagine Mobileye has a better chance of delivering such hyper-growth than Tesla.\nEven after the spinoff of Mobileye, Intel would generate revenues of ~$73B in 2022 with virtually zero impact on its cash flow generation. Although Intel will lose one of its key assets in this transaction (not really, as Intel will still control Mobileye through a majority stake), the proceeds will help Intel's management execute its ambitious growth plans. Using conservative estimates, Intel (minus Mobileye) is still worth ~$70 per share (~$280B market cap) (this valuation exercise is available in my previous articles on Intel). Therefore, the Mobileye spinoff is very likely to unlock hidden value for Intel's shareholders.\nConcluding Thoughts\nWith Intel's market cap hovering at just about $200B, raising capital through stock issuance is not viable. Although Intel's balance sheet and free cash flow generation remain robust, the company is entering a heavy capex-spending cycle, which makes an additional debt raise troublesome. Mobileye is one of the faster-growing business lines at Intel. However, selling a small piece of it could yield a massive sum for Intel, which could be utilized toward Pat Gelsinger's ambitious growth plan for the company. According to my analysis, Mobileye could fetch a valuation of $50B-$100B in the current market environment, and I think Intel will end up raising ~$10B-$15B from the Mobileye IPO while retaining control of the company. I like this move from Intel's management as I can see significant value unlocking from this spinoff.\nIntel is a deeply undervalued cash cow that pays out a healthy, growing dividend. With the Mobileye IPO set to unlock some of Intel's hidden value, I expect to see big capital appreciation in Intel over the next 12-24 months. Therefore, I continue to rate Intel a strong buy at $50.\nKey Takeaway: I rate Intel a strong buy at $50.\nThanks for reading, and happy investing. Please share your thoughts, concerns, and/or questions in the comments section below.","news_type":1},"isVote":1,"tweetType":1,"viewCount":842,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607173423,"gmtCreate":1639517935662,"gmtModify":1639517935782,"author":{"id":"4100520219096230","authorId":"4100520219096230","name":"Piret","avatar":"https://static.tigerbbs.com/32af1c6079ca483ba4808b65db688b5e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100520219096230","idStr":"4100520219096230"},"themes":[],"htmlText":"Okay&nbsp;","listText":"Okay&nbsp;","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607173423","repostId":"2191930972","repostType":4,"repost":{"id":"2191930972","kind":"highlight","pubTimestamp":1639489168,"share":"https://www.laohu8.com/m/news/2191930972?lang=&edition=full","pubTime":"2021-12-14 21:39","market":"us","language":"en","title":"2 Warren Buffett Dividend Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2191930972","media":"Motley Fool","summary":"AbbVie and Royalty Pharma should be on every dividend investor's radar right now.","content":"<p><b>Berkshire Hathaway</b> (NYSE:BRK.A) (NYSE:BRK.B) CEO Warren Buffett is perhaps the best-known value investor of all time. Buffett's concept of value centers around the idea of a deep competitive moat, a sustainable business model, and strong free cash flows.</p>\n<p>As a result, most of Berkshire's top holdings over the past several decades have been well-established companies that offer top-notch shareholder rewards (share repurchases and dividends). Dividends have been particularly important to Berkshire's and Buffett's outstanding gains over the years, as dividends can be used to generate compounding returns when they are reinvested.</p>\n<p>Which Warren Buffett dividend stock picks are the most appealing buys right now? The healthcare stocks <b>AbbVie</b> (NYSE:ABBV) and <b>Royalty Pharma</b> (NASDAQ:RPRX) are two intriguing Berkshire holdings that each pay a respectable dividend. Although these two healthcare stocks are a tad riskier than the average Berkshire investment, there is a solid bull case for both AbbVie and Royalty Pharma right now. Read on to find out more about these two Warren Buffett dividend stock picks.</p>\n<h2>AbbVie: A high-yield growth stock</h2>\n<p>Berkshire first bought AbbVie during the third quarter of 2020. Although Buffett's diversified holding company has since pared back its position in the Illinois-based drugmaker, AbbVie's shares are still a worthwhile buy for most income investors. AbbVie's stock is an appealing income play for three clear-cut reasons. First, the drugmaker pays out a handsome 4.5% dividend yield on an annualized basis. That's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the highest yields among major drug manufacturers.</p>\n<p>Second, AbbVie is a Dividend Aristocrat, meaning that it has a strong track record of raising its dividend on a regular basis. In fact, the company has boosted its yield by a whopping 225% since 2013.</p>\n<p>Lastly, AbbVie has radically transformed its product portfolio ahead of the patent expiration for the flagship anti-inflammatory medicine Humira. The company now has two new high growth immunology assets with Skyrizi and Rinvoq, a strong and growing eye care franchise, several healthy avenues to explore for the commercial expansion of its Allergan aesthetics segment, an underappreciated migraine franchise, and two top-notch oncology drugs with Imbruvica and Venclexta.</p>\n<p>The net result is that AbbVie's top line is forecast to rise by a respectable 6.6% in 2022, despite biosimilar competition for Humira.</p>\n<h2>Royalty Pharma: A dependable revenue stream</h2>\n<p>Royalty Pharma is a brand new addition to the Berkshire family of holdings. The diversified holding company jumped into this pharma stock in the third quarter of 2021 following a sharp pullback in its share price. The backstory is that Royalty went public in the middle of 2020 and initially became a big hit with investors. The company's shares, however, have since reversed course due to the raging political debate over prescription drug prices in the U.S., as well as the negative sentiment toward biopharma stocks in general this year.</p>\n<p><img src=\"https://static.tigerbbs.com/a320f51af9bb7ac0d6359af7ed64161a\" tg-width=\"720\" tg-height=\"449\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>RPRX data by YCharts</p>\n<p>Why is Royalty's stock a bargain at these levels? Although Royalty pays out a less-than-stellar 1.78% annualized dividend yield, the company sports a rock-solid business model. Royalty Pharma makes money by funding late-stage clinical assets in exchange for a share of future revenues. The reason this business model is attractive is because it largely eliminates the risk of investing in either early stage drugmakers or biopharmas with aging portfolios. Royalty, in effect, can cherry-pick the best new growth assets to fund, without having to deal with early to mid-stage clinical setbacks or steep drop-offs in revenue from patent expirations.</p>\n<p>Now, Royalty's dividend yield isn't going to make you rich, but it is a source of reliable income. And that high level of dependability is arguably worth the price of admission alone.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Warren Buffett Dividend Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Warren Buffett Dividend Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-14 21:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/14/2-warren-buffett-dividend-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway (NYSE:BRK.A) (NYSE:BRK.B) CEO Warren Buffett is perhaps the best-known value investor of all time. Buffett's concept of value centers around the idea of a deep competitive moat, a ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/14/2-warren-buffett-dividend-stocks-to-buy-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BRK.A":"伯克希尔","ABBV":"艾伯维公司","BK4533":"AQR资本管理(全球第二大对冲基金)","BRK.B":"伯克希尔B","BK4566":"资本集团","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","BK4176":"多领域控股","BK4139":"生物科技","RPRX":"Royalty Pharma plc","BK4550":"红杉资本持仓","BK4007":"制药"},"source_url":"https://www.fool.com/investing/2021/12/14/2-warren-buffett-dividend-stocks-to-buy-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2191930972","content_text":"Berkshire Hathaway (NYSE:BRK.A) (NYSE:BRK.B) CEO Warren Buffett is perhaps the best-known value investor of all time. Buffett's concept of value centers around the idea of a deep competitive moat, a sustainable business model, and strong free cash flows.\nAs a result, most of Berkshire's top holdings over the past several decades have been well-established companies that offer top-notch shareholder rewards (share repurchases and dividends). Dividends have been particularly important to Berkshire's and Buffett's outstanding gains over the years, as dividends can be used to generate compounding returns when they are reinvested.\nWhich Warren Buffett dividend stock picks are the most appealing buys right now? The healthcare stocks AbbVie (NYSE:ABBV) and Royalty Pharma (NASDAQ:RPRX) are two intriguing Berkshire holdings that each pay a respectable dividend. Although these two healthcare stocks are a tad riskier than the average Berkshire investment, there is a solid bull case for both AbbVie and Royalty Pharma right now. Read on to find out more about these two Warren Buffett dividend stock picks.\nAbbVie: A high-yield growth stock\nBerkshire first bought AbbVie during the third quarter of 2020. Although Buffett's diversified holding company has since pared back its position in the Illinois-based drugmaker, AbbVie's shares are still a worthwhile buy for most income investors. AbbVie's stock is an appealing income play for three clear-cut reasons. First, the drugmaker pays out a handsome 4.5% dividend yield on an annualized basis. That's one of the highest yields among major drug manufacturers.\nSecond, AbbVie is a Dividend Aristocrat, meaning that it has a strong track record of raising its dividend on a regular basis. In fact, the company has boosted its yield by a whopping 225% since 2013.\nLastly, AbbVie has radically transformed its product portfolio ahead of the patent expiration for the flagship anti-inflammatory medicine Humira. The company now has two new high growth immunology assets with Skyrizi and Rinvoq, a strong and growing eye care franchise, several healthy avenues to explore for the commercial expansion of its Allergan aesthetics segment, an underappreciated migraine franchise, and two top-notch oncology drugs with Imbruvica and Venclexta.\nThe net result is that AbbVie's top line is forecast to rise by a respectable 6.6% in 2022, despite biosimilar competition for Humira.\nRoyalty Pharma: A dependable revenue stream\nRoyalty Pharma is a brand new addition to the Berkshire family of holdings. The diversified holding company jumped into this pharma stock in the third quarter of 2021 following a sharp pullback in its share price. The backstory is that Royalty went public in the middle of 2020 and initially became a big hit with investors. The company's shares, however, have since reversed course due to the raging political debate over prescription drug prices in the U.S., as well as the negative sentiment toward biopharma stocks in general this year.\n\nRPRX data by YCharts\nWhy is Royalty's stock a bargain at these levels? Although Royalty pays out a less-than-stellar 1.78% annualized dividend yield, the company sports a rock-solid business model. Royalty Pharma makes money by funding late-stage clinical assets in exchange for a share of future revenues. The reason this business model is attractive is because it largely eliminates the risk of investing in either early stage drugmakers or biopharmas with aging portfolios. Royalty, in effect, can cherry-pick the best new growth assets to fund, without having to deal with early to mid-stage clinical setbacks or steep drop-offs in revenue from patent expirations.\nNow, Royalty's dividend yield isn't going to make you rich, but it is a source of reliable income. And that high level of dependability is arguably worth the price of admission alone.","news_type":1},"isVote":1,"tweetType":1,"viewCount":805,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604544303,"gmtCreate":1639431416598,"gmtModify":1639431416713,"author":{"id":"4100520219096230","authorId":"4100520219096230","name":"Piret","avatar":"https://static.tigerbbs.com/32af1c6079ca483ba4808b65db688b5e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100520219096230","idStr":"4100520219096230"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604544303","repostId":"1101330061","repostType":4,"repost":{"id":"1101330061","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639402663,"share":"https://www.laohu8.com/m/news/1101330061?lang=&edition=full","pubTime":"2021-12-13 21:37","market":"us","language":"en","title":"Veru jumped over 13% in premarket trading as it announced FDA approval of ENTADFI","url":"https://stock-news.laohu8.com/highlight/detail?id=1101330061","media":"Tiger Newspress","summary":"Veru jumped over 13% in premarket trading it announced FDA approval of ENTADFI.The company today ann","content":"<p>Veru jumped over 13% in premarket trading it announced FDA approval of ENTADFI.<img src=\"https://static.tigerbbs.com/fa70bd1f3f0b778ea773bf713c99c679\" tg-width=\"774\" tg-height=\"570\" referrerpolicy=\"no-referrer\">The&nbsp;company&nbsp;today&nbsp;announced that the U.S. Food and Drug Administration (FDA) has approved ENTADFITM&nbsp;for the treatment of urinary tract symptoms caused by an enlarged prostate called benign prostatic hyperplasia (BPH).</p>\n<p>ENTADFI (finasteride and tadalafil) capsule for oral use has also been shown to be more effective to treat urinary tract symptoms caused by BPH with less potential for adverse sexual side effects compared to finasteride monotherapy. ENTADFI dosing is one capsule orally once a day, and the FDA-approved indication is to initiate treatment of the signs and symptoms of benign prostatic hyperplasia in men with an enlarged prostate for up to 26 weeks.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Veru jumped over 13% in premarket trading as it announced FDA approval of ENTADFI</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVeru jumped over 13% in premarket trading as it announced FDA approval of ENTADFI\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-13 21:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Veru jumped over 13% in premarket trading it announced FDA approval of ENTADFI.<img src=\"https://static.tigerbbs.com/fa70bd1f3f0b778ea773bf713c99c679\" tg-width=\"774\" tg-height=\"570\" referrerpolicy=\"no-referrer\">The&nbsp;company&nbsp;today&nbsp;announced that the U.S. Food and Drug Administration (FDA) has approved ENTADFITM&nbsp;for the treatment of urinary tract symptoms caused by an enlarged prostate called benign prostatic hyperplasia (BPH).</p>\n<p>ENTADFI (finasteride and tadalafil) capsule for oral use has also been shown to be more effective to treat urinary tract symptoms caused by BPH with less potential for adverse sexual side effects compared to finasteride monotherapy. ENTADFI dosing is one capsule orally once a day, and the FDA-approved indication is to initiate treatment of the signs and symptoms of benign prostatic hyperplasia in men with an enlarged prostate for up to 26 weeks.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VERU":"Veru Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101330061","content_text":"Veru jumped over 13% in premarket trading it announced FDA approval of ENTADFI.The company today announced that the U.S. Food and Drug Administration (FDA) has approved ENTADFITM for the treatment of urinary tract symptoms caused by an enlarged prostate called benign prostatic hyperplasia (BPH).\nENTADFI (finasteride and tadalafil) capsule for oral use has also been shown to be more effective to treat urinary tract symptoms caused by BPH with less potential for adverse sexual side effects compared to finasteride monotherapy. ENTADFI dosing is one capsule orally once a day, and the FDA-approved indication is to initiate treatment of the signs and symptoms of benign prostatic hyperplasia in men with an enlarged prostate for up to 26 weeks.","news_type":1},"isVote":1,"tweetType":1,"viewCount":894,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605237566,"gmtCreate":1639179735850,"gmtModify":1639179735956,"author":{"id":"4100520219096230","authorId":"4100520219096230","name":"Piret","avatar":"https://static.tigerbbs.com/32af1c6079ca483ba4808b65db688b5e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100520219096230","idStr":"4100520219096230"},"themes":[],"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605237566","repostId":"1199826178","repostType":4,"repost":{"id":"1199826178","kind":"news","pubTimestamp":1639149380,"share":"https://www.laohu8.com/m/news/1199826178?lang=&edition=full","pubTime":"2021-12-10 23:16","market":"us","language":"en","title":"Hedge Funds Ensnared in Expansive DOJ Probe Into Short Selling","url":"https://stock-news.laohu8.com/highlight/detail?id=1199826178","media":"Bloomberg","summary":"Funds and researchers are scrutinized by Justice Department. Inquiry seeks information on trading in several dozen stocks. The U.S. Justice Department has launched an expansive criminal investigation into short selling by hedge funds and research firms, scrutinizing their symbiotic relationships and hunting for signs that they improperly coordinated trades or broke other laws to profit, according to people familiar with the matter.The probe, run by the department’s fraud section with federal pro","content":"<ul>\n <li>Funds and researchers are scrutinized by Justice Department</li>\n <li>Inquiry seeks information on trading in several dozen stocks</li>\n</ul>\n<p>The U.S. Justice Department has launched an expansive criminal investigation into short selling by hedge funds and research firms, scrutinizing their symbiotic relationships and hunting for signs that they improperly coordinated trades or broke other laws to profit, according to people familiar with the matter.</p>\n<p>The probe, run by the department’s fraud section with federal prosecutors in Los Angeles, is digging into how hedge funds tap into research and set up their bets, especially in the run-up to publication of reports that move stocks.</p>\n<p>Authorities are prying into financial relationships between hedge funds and researchers, and hunting for signs that money managers sought to engineer startling stock drops or engaged in other abuses, such as insider trading, said two of the people, asking not to be named because the inquiries are confidential.</p>\n<p>Underscoring the inquiry’s sweep, federal investigators are examining trading in at least several dozen stocks, including well-known short targets such as&nbsp;Luckin Coffee Inc.,Banc of California Inc.,Mallinckrodt Plc&nbsp;and&nbsp;GSX Techedu Inc.And they’re scrutinizing the involvement of about a dozen or more firms -- though it’s not clear which ones, if any, may emerge as targets of the probe. Toronto-based&nbsp;Anson Funds&nbsp;and anonymous researcher Marcus Aurelius Value are among firms involved in the inquiry, the people said. Other prominent firms that circulated research on stocks under scrutiny include Carson Block’s Muddy Waters Capital and Andrew Left’s Citron Research.</p>\n<p>The U.S. probe opens yet another front in an already treacherous era for those who try to profit on stock drops. Some bearish funds&nbsp;threw in the towel&nbsp;as government stimulus buoyed prices during the pandemic. That pressure intensified as retail investors organized counterattacks on popular short targets, bidding up shares to inflictlosseson hedge funds this year. By late January, Citron vowed to give up short-selling research and focus on long bets.</p>\n<p>Meanwhile, companies criticized by short sellers have become increasingly bold in firing back, sometimes launching legal battles even as they face government probes that ultimately support short sellers’ theses. A number of corporate executives have been hoping U.S. authorities might help to further shift the focus to investors’ tactics.</p>\n<p>Still, successfully bringing charges against short sellers could be challenging, given that betting against companies and publishing research believed to be accurate is lawful and even beneficial for markets. So far, nobody has been accused of wrongdoing, and authorities may ultimately decide not to pursue charges.</p>\n<p>Government attorneys are trying to determine whether short sellers engaged in some form of deception -- say, by misleading the public about their financing of what appears to be independent research, violating confidentiality agreements with authors, or orchestrating stock plunges to panic shareholders and exacerbate selling.</p>\n<p>Spokespeople for the Justice Department and Muddy Waters declined to comment, and there was no response to messages sent to Anson Funds and Aurelius.</p>\n<p>An attorney for Citron said he’s aware of an industry probe but that it’s routine for U.S. investigators to open and close cases. He expressed doubt that their theories would be borne out.</p>\n<p>“Citron Capital&nbsp;and Mr. Left are successful because they do quality research and keep their reports secret from other short sellers until publication,” said the lawyer, James Spertus. “There is simply no truth behind any theory that short sellers coordinate amongst themselves before publishing reports, at least in regard to publications by Citron Capital and Andrew Left. I am hopeful that anyone investigating the issue will reach that conclusion as soon as possible.”</p>\n<p><b>Funding Research</b></p>\n<p>Hedge funds are known to strike a wide variety of deals with researchers, sometimes paying handsome subscription fees for fresh insights into possible corporate trouble, or even becoming an author’s primary source of funding. In one example, prominent financial investigator Harry Markopolos, who normally makes money from whistle-blower awards,said&nbsp;he partnered with a hedge fund to share profits when he released a report on&nbsp;General Electric Co.</p>\n<p>Some hedge funds have been known to suggest targets to researchers, who then deliver scathing reports.</p>\n<p>One cautionary tale emerged in court after Dallas-based&nbsp;Sabrepoint Capital&nbsp;agreed to pay a short-selling researcher a monthly retainer of $9,500 in 2018. Sabrepoint encouraged him to dig into real estate company&nbsp;Farmland Partners Inc.The researcher, who also wrote publicly under a pseudonym, later published an article on Seeking Alpha, setting off a 39% drop in Farmland’s share price. The company sued and used a judge’s order to force him to reveal his identity: Quinton Mathews.</p>\n<p>Mathews later said in a statement that he subsequently learned his article “contained inaccuracies and false allegations” and retracted it. He and Farmland reached a settlement. Sabrepoint has said it didn’t know about the Seeking Alpha article.</p>\n<p>Farmland also is on the list of stocks that the Justice Department is examining. Lawyers for Sabrepoint and Mathews declined to comment.</p>\n<p>The Justice Department unit handling the inquiry already has a formidable reputation on Wall Street. It recently brought several cases against global banks and traders for illegal spoofing of precious metals and Treasury futures. As part of that probe,JPMorgan Chase &amp; Co.&nbsp;paid more than $900 million in penalties after its traders placed and canceled orders for commodities to benefit positions held by the bank or prized hedge fund clients. Those cases were brought by analyzing trading data for suspicious patterns and then attributing it to individual traders.</p>\n<p>While prosecutors in the short-selling investigation issued subpoenas as recently as October, the effort has been underway much longer, the people said.</p>\n<p>The inquiry gained momentum after U.S. lawmakers called for more scrutiny of short sellers following the so-called meme-stock trading frenzy that erupted in January. In a single week that month, retail investors sent the price of&nbsp;GameStop Corp.&nbsp;soaring more than 700% before brokerages began limiting bets. Some organizers of the buying spree claimed hedge funds had been unfairly using their market clout to drive down stocks.</p>\n<p>Lawmakers have since held multiple hearings on the fracas, at times discussing whether to force short sellers to boost disclosures.</p>\n<p>Concerns about how short sellers carry out attacks have arisen repeatedly over the years.</p>\n<p>The Securities and Exchange Commission and Justice Department have gone after hedge funds for running “short and distort” campaigns. The practice typically involves setting up bearish bets, then releasing misleading or inaccurate information about a company to drive down the price before closing out the position for a profit.</p>\n<p>But there are also concerns about the impact that earnest research can have when it’s sprung by surprise on the market.</p>\n<p>Studies by Columbia University law professor Joshua Mitts have found that short sellers’ reports can briefly induce bouts of panic selling before shares rebound. In those jittery moments -- sometimes mere minutes or hours -- well-positioned short sellers can cash out of trades and pocket significant gains.</p>\n<p>Mitts examined more than 1,700 reports made by pseudonymous short sellers from 2010 to 2017, concluding that they contributed to more than $20 billion in dislocated values or temporarily mispriced stocks.</p>\n<p>Academics have been encouraging U.S. authorities to address the possibility that short sellers are laying out their cases against stocks, then using the impact of that news to quickly reap gains and quietly move on.</p>\n<p>Early last year, Mitts and about a dozen other prominent securities-law professors urged the SEC to write rules requiring that short sellers who voluntarily reveal bets against a stock be required to disclose when they’ve exited the position. The professors also asked the regulator to write a new rule that would make closing a short position immediately after disseminating a negative report -- with an intent to do so upon publication -- constitute market manipulation.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hedge Funds Ensnared in Expansive DOJ Probe Into Short Selling</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHedge Funds Ensnared in Expansive DOJ Probe Into Short Selling\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-10 23:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-12-10/hedge-funds-ensnared-in-expansive-doj-probe-into-short-selling?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Funds and researchers are scrutinized by Justice Department\nInquiry seeks information on trading in several dozen stocks\n\nThe U.S. Justice Department has launched an expansive criminal investigation ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-12-10/hedge-funds-ensnared-in-expansive-doj-probe-into-short-selling?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite","GE":"GE航空航天","BANC":"BANC OF CALIFORNIA","FPI":"Farmland Partners Inc","GME":"游戏驿站","MNKKQ":"Mallinckrodt plc.",".SPX":"S&P 500 Index","LKNCY":"瑞幸咖啡","GOTU":"高途",".DJI":"道琼斯"},"source_url":"https://www.bloomberg.com/news/articles/2021-12-10/hedge-funds-ensnared-in-expansive-doj-probe-into-short-selling?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199826178","content_text":"Funds and researchers are scrutinized by Justice Department\nInquiry seeks information on trading in several dozen stocks\n\nThe U.S. Justice Department has launched an expansive criminal investigation into short selling by hedge funds and research firms, scrutinizing their symbiotic relationships and hunting for signs that they improperly coordinated trades or broke other laws to profit, according to people familiar with the matter.\nThe probe, run by the department’s fraud section with federal prosecutors in Los Angeles, is digging into how hedge funds tap into research and set up their bets, especially in the run-up to publication of reports that move stocks.\nAuthorities are prying into financial relationships between hedge funds and researchers, and hunting for signs that money managers sought to engineer startling stock drops or engaged in other abuses, such as insider trading, said two of the people, asking not to be named because the inquiries are confidential.\nUnderscoring the inquiry’s sweep, federal investigators are examining trading in at least several dozen stocks, including well-known short targets such as Luckin Coffee Inc.,Banc of California Inc.,Mallinckrodt Plc and GSX Techedu Inc.And they’re scrutinizing the involvement of about a dozen or more firms -- though it’s not clear which ones, if any, may emerge as targets of the probe. Toronto-based Anson Funds and anonymous researcher Marcus Aurelius Value are among firms involved in the inquiry, the people said. Other prominent firms that circulated research on stocks under scrutiny include Carson Block’s Muddy Waters Capital and Andrew Left’s Citron Research.\nThe U.S. probe opens yet another front in an already treacherous era for those who try to profit on stock drops. Some bearish funds threw in the towel as government stimulus buoyed prices during the pandemic. That pressure intensified as retail investors organized counterattacks on popular short targets, bidding up shares to inflictlosseson hedge funds this year. By late January, Citron vowed to give up short-selling research and focus on long bets.\nMeanwhile, companies criticized by short sellers have become increasingly bold in firing back, sometimes launching legal battles even as they face government probes that ultimately support short sellers’ theses. A number of corporate executives have been hoping U.S. authorities might help to further shift the focus to investors’ tactics.\nStill, successfully bringing charges against short sellers could be challenging, given that betting against companies and publishing research believed to be accurate is lawful and even beneficial for markets. So far, nobody has been accused of wrongdoing, and authorities may ultimately decide not to pursue charges.\nGovernment attorneys are trying to determine whether short sellers engaged in some form of deception -- say, by misleading the public about their financing of what appears to be independent research, violating confidentiality agreements with authors, or orchestrating stock plunges to panic shareholders and exacerbate selling.\nSpokespeople for the Justice Department and Muddy Waters declined to comment, and there was no response to messages sent to Anson Funds and Aurelius.\nAn attorney for Citron said he’s aware of an industry probe but that it’s routine for U.S. investigators to open and close cases. He expressed doubt that their theories would be borne out.\n“Citron Capital and Mr. Left are successful because they do quality research and keep their reports secret from other short sellers until publication,” said the lawyer, James Spertus. “There is simply no truth behind any theory that short sellers coordinate amongst themselves before publishing reports, at least in regard to publications by Citron Capital and Andrew Left. I am hopeful that anyone investigating the issue will reach that conclusion as soon as possible.”\nFunding Research\nHedge funds are known to strike a wide variety of deals with researchers, sometimes paying handsome subscription fees for fresh insights into possible corporate trouble, or even becoming an author’s primary source of funding. In one example, prominent financial investigator Harry Markopolos, who normally makes money from whistle-blower awards,said he partnered with a hedge fund to share profits when he released a report on General Electric Co.\nSome hedge funds have been known to suggest targets to researchers, who then deliver scathing reports.\nOne cautionary tale emerged in court after Dallas-based Sabrepoint Capital agreed to pay a short-selling researcher a monthly retainer of $9,500 in 2018. Sabrepoint encouraged him to dig into real estate company Farmland Partners Inc.The researcher, who also wrote publicly under a pseudonym, later published an article on Seeking Alpha, setting off a 39% drop in Farmland’s share price. The company sued and used a judge’s order to force him to reveal his identity: Quinton Mathews.\nMathews later said in a statement that he subsequently learned his article “contained inaccuracies and false allegations” and retracted it. He and Farmland reached a settlement. Sabrepoint has said it didn’t know about the Seeking Alpha article.\nFarmland also is on the list of stocks that the Justice Department is examining. Lawyers for Sabrepoint and Mathews declined to comment.\nThe Justice Department unit handling the inquiry already has a formidable reputation on Wall Street. It recently brought several cases against global banks and traders for illegal spoofing of precious metals and Treasury futures. As part of that probe,JPMorgan Chase & Co. paid more than $900 million in penalties after its traders placed and canceled orders for commodities to benefit positions held by the bank or prized hedge fund clients. Those cases were brought by analyzing trading data for suspicious patterns and then attributing it to individual traders.\nWhile prosecutors in the short-selling investigation issued subpoenas as recently as October, the effort has been underway much longer, the people said.\nThe inquiry gained momentum after U.S. lawmakers called for more scrutiny of short sellers following the so-called meme-stock trading frenzy that erupted in January. In a single week that month, retail investors sent the price of GameStop Corp. soaring more than 700% before brokerages began limiting bets. Some organizers of the buying spree claimed hedge funds had been unfairly using their market clout to drive down stocks.\nLawmakers have since held multiple hearings on the fracas, at times discussing whether to force short sellers to boost disclosures.\nConcerns about how short sellers carry out attacks have arisen repeatedly over the years.\nThe Securities and Exchange Commission and Justice Department have gone after hedge funds for running “short and distort” campaigns. The practice typically involves setting up bearish bets, then releasing misleading or inaccurate information about a company to drive down the price before closing out the position for a profit.\nBut there are also concerns about the impact that earnest research can have when it’s sprung by surprise on the market.\nStudies by Columbia University law professor Joshua Mitts have found that short sellers’ reports can briefly induce bouts of panic selling before shares rebound. In those jittery moments -- sometimes mere minutes or hours -- well-positioned short sellers can cash out of trades and pocket significant gains.\nMitts examined more than 1,700 reports made by pseudonymous short sellers from 2010 to 2017, concluding that they contributed to more than $20 billion in dislocated values or temporarily mispriced stocks.\nAcademics have been encouraging U.S. authorities to address the possibility that short sellers are laying out their cases against stocks, then using the impact of that news to quickly reap gains and quietly move on.\nEarly last year, Mitts and about a dozen other prominent securities-law professors urged the SEC to write rules requiring that short sellers who voluntarily reveal bets against a stock be required to disclose when they’ve exited the position. The professors also asked the regulator to write a new rule that would make closing a short position immediately after disseminating a negative report -- with an intent to do so upon publication -- constitute market manipulation.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1150,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606570499,"gmtCreate":1638912853402,"gmtModify":1638912853551,"author":{"id":"4100520219096230","authorId":"4100520219096230","name":"Piret","avatar":"https://static.tigerbbs.com/32af1c6079ca483ba4808b65db688b5e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100520219096230","idStr":"4100520219096230"},"themes":[],"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606570499","repostId":"1102393012","repostType":4,"repost":{"id":"1102393012","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638882198,"share":"https://www.laohu8.com/m/news/1102393012?lang=&edition=full","pubTime":"2021-12-07 21:03","market":"us","language":"en","title":"Toplines Before US Market Open on Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1102393012","media":"Tiger Newspress","summary":"U.S. stocks looked set to open 1% higher on Tuesday as technology firms bounced back on easing conce","content":"<p>U.S. stocks looked set to open 1% higher on Tuesday as technology firms bounced back on easing concerns around the Omicron variant, while Intel jumped after plans to take its self-driving car unit public.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up 350 points, or 0.99%, S&amp;P 500 e-minis were up 59.75 points, or 1.30%, and Nasdaq 100 e-minis were up 286.25 points, or 1.81%.</p>\n<p><img src=\"https://static.tigerbbs.com/642e33917698c89931671b55c0e9420c\" tg-width=\"1080\" tg-height=\"400\" referrerpolicy=\"no-referrer\"></p>\n<p>Big Tech stocks Google-owner Alphabet,Microsoft, Amazon,Meta Platform&nbsp;and Apple&nbsp;gained nearly 2%.</p>\n<p>Travel shares continued the momentum, with Carnival Corp&nbsp;and United Airlines&nbsp;up 3.6% and 3.4%, respectively, leading the gains among the major airlines and cruise operators.</p>\n<p>Oil stocks including Exxon Mobil&nbsp;and Chevron Corp&nbsp;gained, tracking gains in crude prices.</p>\n<p><b>Stocks making the biggest moves premarket:</b></p>\n<p><b>Intel(INTC) </b>– The chip maker's shares surged 8% in premarket trading after it said it would take its Mobileye self-driving car unit public, planning a mid-2022 initial public offering. The Wall Street Journal had earlier reported those plans, saying an IPO could value Mobileye at more than $50 billion.Other chipmakers <b>Advanced Micro Devices</b><b>(AMD)</b>, <b>Micron Technology</b><b>(MU)</b>&nbsp;and <b>Nvidia</b><b>(NVDA)</b>&nbsp;rose about&nbsp;3%.</p>\n<p><b>Tesla(TSLA) </b>– Tesla is replacing faulty cameras on some of its models, according to internal documents seen by CNBC. The cameras can cause a driver to see a blank or choppy video on a car's primary display. Separately, UBS issued a report that said no rival would come close to Tesla in 2022, although it maintained a \"neutral\" rating on the stock. Tesla gained 3.1% in premarket action.</p>\n<p><b>GlaxoSmithKline(GSK)</b> – Glaxo said early-stage studies showed its antibody therapy for Covid-19 – developed in partnership with U.S.-based<b>&nbsp;Vir Biotechnology(VIR)</b> – is effective against the omicron variant. Vir jumped 6.9% in premarket trading, while Glaxo added 0.6%.</p>\n<p><b>American Airlines(AAL)</b> – Chief Executive Officer Doug Parker announced he would step down from that job on March 31 and remain as chairman. He'll be replaced as CEO by current American Airlines President Robert Isom. American rose 3.4% in the premarket.</p>\n<p><b>Coupa Software(COUP)</b> – The business software company earned an adjusted 31 cents per share for its latest quarter, well above the 2-cent consensus estimate, with revenue also topping forecasts. However, its loss widened from a year ago with a surge in operating expenses, and shares tumbled 8% in premarket trading.</p>\n<p><b>Bumble(BMBL)</b> – The dating service operator's shares rallied 6.8% in the premarket after J.P. Morgan Securities upgraded the stock to \"overweight\" from \"neutral\" following a meeting with management. The firm said it was now more confident in the growth trajectory and prospects for user engagement with the Bumble app.</p>\n<p><b>AutoZone(AZO)</b> – The auto parts retailer reported a quarterly profit of $25.69 per share, beating the consensus estimate of $20.87. Revenue also beat estimates, with comparable store sales jumping 13.6%. Analysts surveyed by StreetAccount had predicted a comp-store sales rise of 5%.</p>\n<p><b>Designer Brands(DBI)</b> – The footwear retailer beat estimates by 30 cents with adjusted quarterly earnings of 86 cents per share, but revenue fell short of Wall Street forecasts. Comparable store sales did surge by 40.8%, but that was less than the 44.5% analysts had anticipated. Nonetheless, shares rallied 7.4% in premarket trading.</p>\n<p><b>Constellation Brands(STZ) </b>– The brewer of Corona beer agreed to build a new brewery in southeastern Mexico, according to a Wall Street Journal report. The agreement – set to be announced as early as this week – comes two years after the government forced Constellation to close a nearly completed plant near the U.S.-Mexican border.</p>\n<p><b>Mimecast(MIME)</b> – The cybersecurity company agreed to be acquired by private equity firm Permira for $80 per share in cash, or about $5.8 billion. Mimecast jumped 6.7% in the premarket.</p>\n<p><b>MongoDB(MDB)</b> – MongoDB surged 21.4% in premarket action after the database platform company reported a smaller-than-expected quarterly loss and beat Street revenue forecasts. MongoDB also raised its financial outlook for the year on increased demand from businesses for online connectivity.</p>\n<p><b>Acadia Pharmaceuticals(ACAD) </b>– Acadia soared 17.3% in the premarket after announcing positive results in a late-stage trial of its experimental treatment for Rett Syndrome, a genetic disorder that primarily affects brain development in girls.</p>\n<p><b>Jack In The Box(JACK)</b> – Jack In The Box was upgraded to \"buy\" from \"hold\" at Deutsche Bank, which said the restaurant operator's acquisition of Mexican food chain&nbsp;Del Taco(TACO) makes sense. Jack In The Box shares had fallen more than 4% Monday after the deal was announced. Jack In The Box gained 1.6% in premarket trading.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Tuesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Tuesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-07 21:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S. stocks looked set to open 1% higher on Tuesday as technology firms bounced back on easing concerns around the Omicron variant, while Intel jumped after plans to take its self-driving car unit public.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up 350 points, or 0.99%, S&amp;P 500 e-minis were up 59.75 points, or 1.30%, and Nasdaq 100 e-minis were up 286.25 points, or 1.81%.</p>\n<p><img src=\"https://static.tigerbbs.com/642e33917698c89931671b55c0e9420c\" tg-width=\"1080\" tg-height=\"400\" referrerpolicy=\"no-referrer\"></p>\n<p>Big Tech stocks Google-owner Alphabet,Microsoft, Amazon,Meta Platform&nbsp;and Apple&nbsp;gained nearly 2%.</p>\n<p>Travel shares continued the momentum, with Carnival Corp&nbsp;and United Airlines&nbsp;up 3.6% and 3.4%, respectively, leading the gains among the major airlines and cruise operators.</p>\n<p>Oil stocks including Exxon Mobil&nbsp;and Chevron Corp&nbsp;gained, tracking gains in crude prices.</p>\n<p><b>Stocks making the biggest moves premarket:</b></p>\n<p><b>Intel(INTC) </b>– The chip maker's shares surged 8% in premarket trading after it said it would take its Mobileye self-driving car unit public, planning a mid-2022 initial public offering. The Wall Street Journal had earlier reported those plans, saying an IPO could value Mobileye at more than $50 billion.Other chipmakers <b>Advanced Micro Devices</b><b>(AMD)</b>, <b>Micron Technology</b><b>(MU)</b>&nbsp;and <b>Nvidia</b><b>(NVDA)</b>&nbsp;rose about&nbsp;3%.</p>\n<p><b>Tesla(TSLA) </b>– Tesla is replacing faulty cameras on some of its models, according to internal documents seen by CNBC. The cameras can cause a driver to see a blank or choppy video on a car's primary display. Separately, UBS issued a report that said no rival would come close to Tesla in 2022, although it maintained a \"neutral\" rating on the stock. Tesla gained 3.1% in premarket action.</p>\n<p><b>GlaxoSmithKline(GSK)</b> – Glaxo said early-stage studies showed its antibody therapy for Covid-19 – developed in partnership with U.S.-based<b>&nbsp;Vir Biotechnology(VIR)</b> – is effective against the omicron variant. Vir jumped 6.9% in premarket trading, while Glaxo added 0.6%.</p>\n<p><b>American Airlines(AAL)</b> – Chief Executive Officer Doug Parker announced he would step down from that job on March 31 and remain as chairman. He'll be replaced as CEO by current American Airlines President Robert Isom. American rose 3.4% in the premarket.</p>\n<p><b>Coupa Software(COUP)</b> – The business software company earned an adjusted 31 cents per share for its latest quarter, well above the 2-cent consensus estimate, with revenue also topping forecasts. However, its loss widened from a year ago with a surge in operating expenses, and shares tumbled 8% in premarket trading.</p>\n<p><b>Bumble(BMBL)</b> – The dating service operator's shares rallied 6.8% in the premarket after J.P. Morgan Securities upgraded the stock to \"overweight\" from \"neutral\" following a meeting with management. The firm said it was now more confident in the growth trajectory and prospects for user engagement with the Bumble app.</p>\n<p><b>AutoZone(AZO)</b> – The auto parts retailer reported a quarterly profit of $25.69 per share, beating the consensus estimate of $20.87. Revenue also beat estimates, with comparable store sales jumping 13.6%. Analysts surveyed by StreetAccount had predicted a comp-store sales rise of 5%.</p>\n<p><b>Designer Brands(DBI)</b> – The footwear retailer beat estimates by 30 cents with adjusted quarterly earnings of 86 cents per share, but revenue fell short of Wall Street forecasts. Comparable store sales did surge by 40.8%, but that was less than the 44.5% analysts had anticipated. Nonetheless, shares rallied 7.4% in premarket trading.</p>\n<p><b>Constellation Brands(STZ) </b>– The brewer of Corona beer agreed to build a new brewery in southeastern Mexico, according to a Wall Street Journal report. The agreement – set to be announced as early as this week – comes two years after the government forced Constellation to close a nearly completed plant near the U.S.-Mexican border.</p>\n<p><b>Mimecast(MIME)</b> – The cybersecurity company agreed to be acquired by private equity firm Permira for $80 per share in cash, or about $5.8 billion. Mimecast jumped 6.7% in the premarket.</p>\n<p><b>MongoDB(MDB)</b> – MongoDB surged 21.4% in premarket action after the database platform company reported a smaller-than-expected quarterly loss and beat Street revenue forecasts. MongoDB also raised its financial outlook for the year on increased demand from businesses for online connectivity.</p>\n<p><b>Acadia Pharmaceuticals(ACAD) </b>– Acadia soared 17.3% in the premarket after announcing positive results in a late-stage trial of its experimental treatment for Rett Syndrome, a genetic disorder that primarily affects brain development in girls.</p>\n<p><b>Jack In The Box(JACK)</b> – Jack In The Box was upgraded to \"buy\" from \"hold\" at Deutsche Bank, which said the restaurant operator's acquisition of Mexican food chain&nbsp;Del Taco(TACO) makes sense. Jack In The Box shares had fallen more than 4% Monday after the deal was announced. Jack In The Box gained 1.6% in premarket trading.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COUP":"Coupa Software Inc","AZO":"汽车地带","STZ":"星座品牌","NVDA":"英伟达","MIME":"Mimecast Ltd","ACAD":"阿卡迪亚","BMBL":"Bumble Inc.","GSK":"葛兰素史克",".SPX":"S&P 500 Index","AMD":"美国超微公司","AAL":"美国航空","DBI":"Designer Brands Inc","MU":"美光科技","JACK":"Jack In The Box Inc","TSLA":"特斯拉","MDB":"MongoDB Inc.",".DJI":"道琼斯","INTC":"英特尔",".IXIC":"NASDAQ Composite"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102393012","content_text":"U.S. stocks looked set to open 1% higher on Tuesday as technology firms bounced back on easing concerns around the Omicron variant, while Intel jumped after plans to take its self-driving car unit public.\nAt 8:00 a.m. ET, Dow e-minis were up 350 points, or 0.99%, S&P 500 e-minis were up 59.75 points, or 1.30%, and Nasdaq 100 e-minis were up 286.25 points, or 1.81%.\n\nBig Tech stocks Google-owner Alphabet,Microsoft, Amazon,Meta Platform and Apple gained nearly 2%.\nTravel shares continued the momentum, with Carnival Corp and United Airlines up 3.6% and 3.4%, respectively, leading the gains among the major airlines and cruise operators.\nOil stocks including Exxon Mobil and Chevron Corp gained, tracking gains in crude prices.\nStocks making the biggest moves premarket:\nIntel(INTC) – The chip maker's shares surged 8% in premarket trading after it said it would take its Mobileye self-driving car unit public, planning a mid-2022 initial public offering. The Wall Street Journal had earlier reported those plans, saying an IPO could value Mobileye at more than $50 billion.Other chipmakers Advanced Micro Devices(AMD), Micron Technology(MU) and Nvidia(NVDA) rose about 3%.\nTesla(TSLA) – Tesla is replacing faulty cameras on some of its models, according to internal documents seen by CNBC. The cameras can cause a driver to see a blank or choppy video on a car's primary display. Separately, UBS issued a report that said no rival would come close to Tesla in 2022, although it maintained a \"neutral\" rating on the stock. Tesla gained 3.1% in premarket action.\nGlaxoSmithKline(GSK) – Glaxo said early-stage studies showed its antibody therapy for Covid-19 – developed in partnership with U.S.-based Vir Biotechnology(VIR) – is effective against the omicron variant. Vir jumped 6.9% in premarket trading, while Glaxo added 0.6%.\nAmerican Airlines(AAL) – Chief Executive Officer Doug Parker announced he would step down from that job on March 31 and remain as chairman. He'll be replaced as CEO by current American Airlines President Robert Isom. American rose 3.4% in the premarket.\nCoupa Software(COUP) – The business software company earned an adjusted 31 cents per share for its latest quarter, well above the 2-cent consensus estimate, with revenue also topping forecasts. However, its loss widened from a year ago with a surge in operating expenses, and shares tumbled 8% in premarket trading.\nBumble(BMBL) – The dating service operator's shares rallied 6.8% in the premarket after J.P. Morgan Securities upgraded the stock to \"overweight\" from \"neutral\" following a meeting with management. The firm said it was now more confident in the growth trajectory and prospects for user engagement with the Bumble app.\nAutoZone(AZO) – The auto parts retailer reported a quarterly profit of $25.69 per share, beating the consensus estimate of $20.87. Revenue also beat estimates, with comparable store sales jumping 13.6%. Analysts surveyed by StreetAccount had predicted a comp-store sales rise of 5%.\nDesigner Brands(DBI) – The footwear retailer beat estimates by 30 cents with adjusted quarterly earnings of 86 cents per share, but revenue fell short of Wall Street forecasts. Comparable store sales did surge by 40.8%, but that was less than the 44.5% analysts had anticipated. Nonetheless, shares rallied 7.4% in premarket trading.\nConstellation Brands(STZ) – The brewer of Corona beer agreed to build a new brewery in southeastern Mexico, according to a Wall Street Journal report. The agreement – set to be announced as early as this week – comes two years after the government forced Constellation to close a nearly completed plant near the U.S.-Mexican border.\nMimecast(MIME) – The cybersecurity company agreed to be acquired by private equity firm Permira for $80 per share in cash, or about $5.8 billion. Mimecast jumped 6.7% in the premarket.\nMongoDB(MDB) – MongoDB surged 21.4% in premarket action after the database platform company reported a smaller-than-expected quarterly loss and beat Street revenue forecasts. MongoDB also raised its financial outlook for the year on increased demand from businesses for online connectivity.\nAcadia Pharmaceuticals(ACAD) – Acadia soared 17.3% in the premarket after announcing positive results in a late-stage trial of its experimental treatment for Rett Syndrome, a genetic disorder that primarily affects brain development in girls.\nJack In The Box(JACK) – Jack In The Box was upgraded to \"buy\" from \"hold\" at Deutsche Bank, which said the restaurant operator's acquisition of Mexican food chain Del Taco(TACO) makes sense. Jack In The Box shares had fallen more than 4% Monday after the deal was announced. Jack In The Box gained 1.6% in premarket trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":888,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606927618,"gmtCreate":1638825874594,"gmtModify":1638825874594,"author":{"id":"4100520219096230","authorId":"4100520219096230","name":"Piret","avatar":"https://static.tigerbbs.com/32af1c6079ca483ba4808b65db688b5e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100520219096230","idStr":"4100520219096230"},"themes":[],"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606927618","repostId":"1163923112","repostType":4,"repost":{"id":"1163923112","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1638797491,"share":"https://www.laohu8.com/m/news/1163923112?lang=&edition=full","pubTime":"2021-12-06 21:31","market":"us","language":"en","title":"10 Biggest Price Target Changes For Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1163923112","media":"Benzinga","summary":"Cowen & Co. raised the price target on The Boston Beer Company, Inc.(NYSE:SAM) from $400 to $500. Bo","content":"<ul>\n <li>Cowen &amp; Co. raised the price target on&nbsp;<b>The Boston Beer Company, Inc.</b>(NYSE:SAM) from $400 to $500. Boston Beer shares rose 1% to $465.20 in pre-market trading.</li>\n <li>Keybanc lowered&nbsp;<b>Darden Restaurants, Inc.</b>(NYSE:DRI) price target from $180 to $172. Darden shares fell 0.5% to close at $142.35 on Friday.</li>\n <li>Barclays lifted&nbsp;<b>Ulta Beauty, Inc.</b>(NASDAQ:ULTA) price target from $492 to $516. Ulta Beauty shares rose 0.6% to $380.90 pre-market trading.</li>\n <li>Oppenheimer raised the price target on&nbsp;<b>Lowe's Companies, Inc.</b>(NYSE:LOW) from $235 to $300. Lowe's Companies shares rose 0.9% to $250.89 in pre-market trading.</li>\n <li>Telsey Advisory Group cut&nbsp;<b>Big Lots, Inc.</b>(NYSE:BIG) price target from $57 to $55. Big Lots shares rose 2.3% to $47.01 in pre-market trading.</li>\n <li>Morgan Stanley boosted the price target for&nbsp;<b>SVB Financial Group</b>(NASDAQ:SIVB) from $775 to $985. Morgan Stanley shares fell 5.3% to close at $674.57 on Friday.</li>\n <li>Goldman Sachs cut&nbsp;<b>Accel Entertainment, Inc.</b>(NYSE:ACEL) price target from $15.5 to $14.5. Accel Entertainment shares rose 2.9% to close at $12.96 on Friday.</li>\n <li>Raymond James lowered the price target on&nbsp;<b>Laredo Petroleum, Inc.</b>(NYSE:LPI) from $105 to $85. Laredo Petroleum shares climbed 2.5% to $56.79 in pre-market trading.</li>\n <li>Piper Sandler increased the price target for&nbsp;<b>Steven Madden, Ltd.</b>(NASDAQ:SHOO) from $54 to $56. Steven Madden shares rose 1.6% to $46.78 in pre-market trading.</li>\n <li>Credit Suisse lowered&nbsp;<b>Esperion Therapeutics, Inc.</b>(NASDAQ:ESPR) price target from $11 to $8. Esperion Therapeutics shares fell 0.6% to $5.22 in pre-market trading.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-06 21:31</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li>Cowen &amp; Co. raised the price target on&nbsp;<b>The Boston Beer Company, Inc.</b>(NYSE:SAM) from $400 to $500. Boston Beer shares rose 1% to $465.20 in pre-market trading.</li>\n <li>Keybanc lowered&nbsp;<b>Darden Restaurants, Inc.</b>(NYSE:DRI) price target from $180 to $172. Darden shares fell 0.5% to close at $142.35 on Friday.</li>\n <li>Barclays lifted&nbsp;<b>Ulta Beauty, Inc.</b>(NASDAQ:ULTA) price target from $492 to $516. Ulta Beauty shares rose 0.6% to $380.90 pre-market trading.</li>\n <li>Oppenheimer raised the price target on&nbsp;<b>Lowe's Companies, Inc.</b>(NYSE:LOW) from $235 to $300. Lowe's Companies shares rose 0.9% to $250.89 in pre-market trading.</li>\n <li>Telsey Advisory Group cut&nbsp;<b>Big Lots, Inc.</b>(NYSE:BIG) price target from $57 to $55. Big Lots shares rose 2.3% to $47.01 in pre-market trading.</li>\n <li>Morgan Stanley boosted the price target for&nbsp;<b>SVB Financial Group</b>(NASDAQ:SIVB) from $775 to $985. Morgan Stanley shares fell 5.3% to close at $674.57 on Friday.</li>\n <li>Goldman Sachs cut&nbsp;<b>Accel Entertainment, Inc.</b>(NYSE:ACEL) price target from $15.5 to $14.5. Accel Entertainment shares rose 2.9% to close at $12.96 on Friday.</li>\n <li>Raymond James lowered the price target on&nbsp;<b>Laredo Petroleum, Inc.</b>(NYSE:LPI) from $105 to $85. Laredo Petroleum shares climbed 2.5% to $56.79 in pre-market trading.</li>\n <li>Piper Sandler increased the price target for&nbsp;<b>Steven Madden, Ltd.</b>(NASDAQ:SHOO) from $54 to $56. Steven Madden shares rose 1.6% to $46.78 in pre-market trading.</li>\n <li>Credit Suisse lowered&nbsp;<b>Esperion Therapeutics, Inc.</b>(NASDAQ:ESPR) price target from $11 to $8. Esperion Therapeutics shares fell 0.6% to $5.22 in pre-market trading.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LOW":"劳氏","SHOO":"史蒂夫·马登","ACEL":"Accel Entertainment Inc","SAM":"波斯顿啤酒","ULTA":"Ulta美容","DRI":"达登饭店","BIG":"必乐透","ESPR":"Esperion Therapeutics Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163923112","content_text":"Cowen & Co. raised the price target on The Boston Beer Company, Inc.(NYSE:SAM) from $400 to $500. Boston Beer shares rose 1% to $465.20 in pre-market trading.\nKeybanc lowered Darden Restaurants, Inc.(NYSE:DRI) price target from $180 to $172. Darden shares fell 0.5% to close at $142.35 on Friday.\nBarclays lifted Ulta Beauty, Inc.(NASDAQ:ULTA) price target from $492 to $516. Ulta Beauty shares rose 0.6% to $380.90 pre-market trading.\nOppenheimer raised the price target on Lowe's Companies, Inc.(NYSE:LOW) from $235 to $300. Lowe's Companies shares rose 0.9% to $250.89 in pre-market trading.\nTelsey Advisory Group cut Big Lots, Inc.(NYSE:BIG) price target from $57 to $55. Big Lots shares rose 2.3% to $47.01 in pre-market trading.\nMorgan Stanley boosted the price target for SVB Financial Group(NASDAQ:SIVB) from $775 to $985. Morgan Stanley shares fell 5.3% to close at $674.57 on Friday.\nGoldman Sachs cut Accel Entertainment, Inc.(NYSE:ACEL) price target from $15.5 to $14.5. Accel Entertainment shares rose 2.9% to close at $12.96 on Friday.\nRaymond James lowered the price target on Laredo Petroleum, Inc.(NYSE:LPI) from $105 to $85. Laredo Petroleum shares climbed 2.5% to $56.79 in pre-market trading.\nPiper Sandler increased the price target for Steven Madden, Ltd.(NASDAQ:SHOO) from $54 to $56. Steven Madden shares rose 1.6% to $46.78 in pre-market trading.\nCredit Suisse lowered Esperion Therapeutics, Inc.(NASDAQ:ESPR) price target from $11 to $8. Esperion Therapeutics shares fell 0.6% to $5.22 in pre-market trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1053,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609085204,"gmtCreate":1638222370932,"gmtModify":1638222371047,"author":{"id":"4100520219096230","authorId":"4100520219096230","name":"Piret","avatar":"https://static.tigerbbs.com/32af1c6079ca483ba4808b65db688b5e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100520219096230","idStr":"4100520219096230"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609085204","repostId":"2186262293","repostType":4,"isVote":1,"tweetType":1,"viewCount":1003,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872701641,"gmtCreate":1637569518835,"gmtModify":1637569518835,"author":{"id":"4100520219096230","authorId":"4100520219096230","name":"Piret","avatar":"https://static.tigerbbs.com/32af1c6079ca483ba4808b65db688b5e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100520219096230","idStr":"4100520219096230"},"themes":[],"htmlText":"Like plsThank you","listText":"Like plsThank you","text":"Like plsThank you","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/872701641","repostId":"2185295758","repostType":4,"repost":{"id":"2185295758","kind":"highlight","pubTimestamp":1637536143,"share":"https://www.laohu8.com/m/news/2185295758?lang=&edition=full","pubTime":"2021-11-22 07:09","market":"us","language":"en","title":"Here's what history says about stock-market performance during the Thanksgiving week","url":"https://stock-news.laohu8.com/highlight/detail?id=2185295758","media":"MarketWatch","summary":"Will it be gobble, gobble for U.S. stock-market investors during the Thanksgiving week or an overdos","content":"<p>Will it be gobble, gobble for U.S. stock-market investors during the Thanksgiving week or an overdose of tryptophan?</p>\n<p>That’s the question that some may be considering as Wall Street completes the last full week of trading in November and gears up for a holiday period that is typically characterized by some of the lowest volumes of the year.</p>\n<p>U.S. financial markets are closed on Thursday, Nov. 26 for the Thanksgiving holiday and beyond Thursday’s closure, since 1992, stock exchanges have adhered to an abbreviated trading schedule the Friday after Thanksgiving in the U.S.</p>\n<p>The New York Stock Exchange and the Nasdaq will close at 1 p.m. Eastern time on Friday, while the Securities Industry and Financial Markets Association recommends a 2 p.m. Eastern close for U.S. bond markets.</p>\n<p>Against that backdrop, Thanksgiving has become synonymous with low-volume trading, which can sometimes lead to choppy action.</p>\n<p>So how has the market performed in this scenerio? Not bad?</p>\n<p>The folks at Bespoke Investment Group say that Thanksgiving week has lent itself to a modest gain for stocks dating back to 1945.</p>\n<p>The researchers say that since that point, “the entire week of Thanksgiving has averaged a 60 basis points, or 0.60 percentage point, advance for the S&amp;P 500,with the best returns coming on Wednesday before the holiday and Black Friday, and the only decline on average on Monday, the start of the week.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9898cb0063474d1f44e9939d67ff509f\" tg-width=\"699\" tg-height=\"406\" width=\"100%\" height=\"auto\"><span>BESPOKE INVESTMENT GROUP</span></p>\n<p>Bespoke, however, says that more recently, gains have shifted to Mondays in Thanksgiving week, with small declines on Tuesday and rallies on the last two days of the session.</p>\n<p>The prospects of gains may be heartening to investors considering the prospect of inflation fears and uncertainty about the leadership of the Federal Reserve, with President Biden expected to decide whether to extend Jerome Powell’s tenure as Fed chairman, which ends in Feburary or possible turn to Fed Gov. Lael Brainard.</p>\n<p>Markets closed mostly lower on the Friday before Thanksgiving, with the S&amp;P 500&nbsp;booking a gain of 0.4%, the Nasdaq Composite&nbsp;posting a weekly gain of 1.2% and the Dow Jones Industrial Average&nbsp;closing ending lower for a second week in a row, off 1.4%.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's what history says about stock-market performance during the Thanksgiving week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's what history says about stock-market performance during the Thanksgiving week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-22 07:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/heres-what-history-says-about-stock-market-performance-during-the-thanksgiving-week-11637356248?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Will it be gobble, gobble for U.S. stock-market investors during the Thanksgiving week or an overdose of tryptophan?\nThat’s the question that some may be considering as Wall Street completes the last ...</p>\n\n<a href=\"https://www.marketwatch.com/story/heres-what-history-says-about-stock-market-performance-during-the-thanksgiving-week-11637356248?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"source_url":"https://www.marketwatch.com/story/heres-what-history-says-about-stock-market-performance-during-the-thanksgiving-week-11637356248?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2185295758","content_text":"Will it be gobble, gobble for U.S. stock-market investors during the Thanksgiving week or an overdose of tryptophan?\nThat’s the question that some may be considering as Wall Street completes the last full week of trading in November and gears up for a holiday period that is typically characterized by some of the lowest volumes of the year.\nU.S. financial markets are closed on Thursday, Nov. 26 for the Thanksgiving holiday and beyond Thursday’s closure, since 1992, stock exchanges have adhered to an abbreviated trading schedule the Friday after Thanksgiving in the U.S.\nThe New York Stock Exchange and the Nasdaq will close at 1 p.m. Eastern time on Friday, while the Securities Industry and Financial Markets Association recommends a 2 p.m. Eastern close for U.S. bond markets.\nAgainst that backdrop, Thanksgiving has become synonymous with low-volume trading, which can sometimes lead to choppy action.\nSo how has the market performed in this scenerio? Not bad?\nThe folks at Bespoke Investment Group say that Thanksgiving week has lent itself to a modest gain for stocks dating back to 1945.\nThe researchers say that since that point, “the entire week of Thanksgiving has averaged a 60 basis points, or 0.60 percentage point, advance for the S&P 500,with the best returns coming on Wednesday before the holiday and Black Friday, and the only decline on average on Monday, the start of the week.\nBESPOKE INVESTMENT GROUP\nBespoke, however, says that more recently, gains have shifted to Mondays in Thanksgiving week, with small declines on Tuesday and rallies on the last two days of the session.\nThe prospects of gains may be heartening to investors considering the prospect of inflation fears and uncertainty about the leadership of the Federal Reserve, with President Biden expected to decide whether to extend Jerome Powell’s tenure as Fed chairman, which ends in Feburary or possible turn to Fed Gov. Lael Brainard.\nMarkets closed mostly lower on the Friday before Thanksgiving, with the S&P 500 booking a gain of 0.4%, the Nasdaq Composite posting a weekly gain of 1.2% and the Dow Jones Industrial Average closing ending lower for a second week in a row, off 1.4%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":986,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872454550,"gmtCreate":1637565222066,"gmtModify":1637565222239,"author":{"id":"4100520219096230","authorId":"4100520219096230","name":"Piret","avatar":"https://static.tigerbbs.com/32af1c6079ca483ba4808b65db688b5e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4100520219096230","idStr":"4100520219096230"},"themes":[],"htmlText":"Like pls, thank you","listText":"Like pls, thank you","text":"Like pls, thank you","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/872454550","repostId":"1174499408","repostType":4,"isVote":1,"tweetType":1,"viewCount":427,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":872454550,"gmtCreate":1637565222066,"gmtModify":1637565222239,"author":{"id":"4100520219096230","authorId":"4100520219096230","name":"Piret","avatar":"https://static.tigerbbs.com/32af1c6079ca483ba4808b65db688b5e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100520219096230","authorIdStr":"4100520219096230"},"themes":[],"htmlText":"Like pls, thank you","listText":"Like pls, thank you","text":"Like pls, thank you","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/872454550","repostId":"1174499408","repostType":4,"isVote":1,"tweetType":1,"viewCount":427,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699006758,"gmtCreate":1639716801585,"gmtModify":1639716801682,"author":{"id":"4100520219096230","authorId":"4100520219096230","name":"Piret","avatar":"https://static.tigerbbs.com/32af1c6079ca483ba4808b65db688b5e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100520219096230","authorIdStr":"4100520219096230"},"themes":[],"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699006758","repostId":"1169026598","repostType":4,"isVote":1,"tweetType":1,"viewCount":842,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609085204,"gmtCreate":1638222370932,"gmtModify":1638222371047,"author":{"id":"4100520219096230","authorId":"4100520219096230","name":"Piret","avatar":"https://static.tigerbbs.com/32af1c6079ca483ba4808b65db688b5e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100520219096230","authorIdStr":"4100520219096230"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/609085204","repostId":"2186262293","repostType":4,"repost":{"id":"2186262293","kind":"highlight","pubTimestamp":1638155027,"share":"https://www.laohu8.com/m/news/2186262293?lang=&edition=full","pubTime":"2021-11-29 11:03","market":"us","language":"en","title":"Better Semiconductor Stock: Nvidia or AMD","url":"https://stock-news.laohu8.com/highlight/detail?id=2186262293","media":"Motley Fool","summary":"Which high-growth chipmaker is the better all-around investment?","content":"<p><b>Key Points</b></p>\n<ul>\n <li>Nvidia is profiting from the robust demand for GPUs in the gaming and data center markets.</li>\n <li>AMD is selling more CPUs for the PC and server markets as Intel tries to resolve its R&amp;D and manufacturing issues.</li>\n <li>One of these chipmakers has more catalysts than the other.</li>\n</ul>\n<p>Last December, I compared two of the market's hottest semiconductor stocks: <b>Nvidia</b> (NASDAQ:NVDA) and <b>Advanced Micro Devices</b> (NASDAQ:<a href=\"https://laohu8.com/S/AMD\">AMD</a>).</p>\n<p>At the time, I said AMD was a better buy than Nvidia because I believed it was better insulated from macro headwinds, it would benefit from the arrivals of the new PlayStation 5 and Xbox Series consoles, and it would continue to grow its market share against <b>Intel </b>(NASDAQ:INTC).</p>\n<p>However, Nvidia's stock price has rallied nearly 150% since I wrote that article, while AMD's stock has only advanced about 70%. Let's take a fresh look at both chipmakers to see if I made the wrong call last year.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9c23cc7b86d5f4cdb564f53ac3e85040\" tg-width=\"2000\" tg-height=\"1125\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p>\n<h2>What I got wrong about Nvidia</h2>\n<p>I had expected Nvidia's gaming and data center GPU businesses, which both experienced strong growth during the pandemic, to lose their momentum as the pandemic passed, people played fewer games, and data centers faced less pressure to upgrade their AI-processing servers. But that slowdown never happened.</p>\n<p>Nvidia's revenue rose 53% to $16.7 billion in fiscal 2021, which ended back in January. That growth was led by its gaming and data center businesses, which easily offset the slower growth of its auto, professional visualization, and OEM businesses. Its adjusted gross margin expanded 310 basis points to 65.6%, while its adjusted net income surged 75% to $6.3 billion.</p>\n<p>In the first nine months of fiscal 2022, Nvidia's revenue grew 65% year over year to $19.3 billion. Its gaming and data center businesses continued to grow, while its auto, professional visualization, and OEM segments all recovered as the pandemic-related headwinds waned. Its data center business also benefited from its takeover of the data center networking equipment maker Mellanox last April. Its adjusted gross margin rose 90 basis points year over year to 66.6%, and its adjusted net income jumped 83% to $7.9 billion.</p>\n<p>Analysts expect Nvidia's revenue and earnings to grow 60% and 74%, respectively, for the full year. Those estimates notably don't factor in the potential success or failure of its $40 billion takeover bid for Arm Holdings from <b>Softbank</b>, which could be stuck in regulatory limbo&nbsp;for the foreseeable future.</p>\n<h2>What I got wrong about AMD</h2>\n<p>AMD performed very well&nbsp;over the past year, but it didn't actually gain much ground against Intel in the CPU market. Between the fourth quarters of 2020 and 2021, Intel's market share rose from 61.5% to 62.1%, according to PassMark, while AMD's share dipped from 38.5% to 37.8%.</p>\n<p>AMD's share of the discrete GPU market also dipped from 20% to 17% between the third quarters of 2020 and 2021, according to JPR. Nvidia's share rose from 80% to 83%. AMD benefited from robust sales of <b>Sony</b>&nbsp;and <b>Microsoft</b>'s new gaming consoles this year, but the ongoing supply chain shortages are capping those gains.</p>\n<p>Yet AMD continues to grow. Last year, its revenue rose 45% to $9.76 billion, Its adjusted gross margin expanded two percentage points to 45%, and its adjusted net income more than doubled to $1.58 billion.</p>\n<p>In the first nine months of 2021, its revenue grew 78% year-over-year to $11.6 billion, its adjusted gross margin rose from 44% to 47%, and its adjusted net income soared 146% to $2.31 billion. It attributed most of that growth to robust sales of its Ryzen CPUs for PCs and Epyc CPUs for servers.</p>\n<p>Analysts expect AMD's revenue and adjusted earnings to increase 65% and 104%, respectively, for the full year. Those estimates don't include its planned purchase of <b>Xilinx</b> (NASDAQ:XLNX), which will complement its Eypc data center business with programmable chips.</p>\n<h2>The valuations and upcoming challenges</h2>\n<p>Nvidia trades at 62 times forward earnings, while AMD has a lower forward price-to-earnings ratio of 46. Analysts expect both chipmakers to generate slower growth next year, but Nvidia might have more catalysts than AMD.</p>\n<p>Nvidia's core GPU business remains far ahead of AMD's, and the secular strength of the gaming and data center markets -- along with the recovery of its smaller end markets -- should support its long-term growth.</p>\n<p>AMD is still a thorn in Intel's side, and it remains ahead of its larger CPU rival in the \"process race\" to create smaller and more advanced chips because it outsources its production to <b>Taiwan Semiconductor Manufacturing</b> (NYSE:TSM). However, that balance could eventually shift as Intel doubles down on its own first-party manufacturing efforts and tries to catch up to TSMC.</p>\n<p>That looming threat, along with intense competition from Nvidia in the GPU market, could be preventing investors from paying a higher premium for AMD's stock, even though it's growing at a comparable rate as Nvidia.</p>\n<p>AMD's planned takeover of Xilinx, which mirrors Intel's takeover of Altera six years ago, is also arguably more important to its long-term growth plans than Nvidia's planned purchase of Arm -- which would merely complement its existing business with new CPU design and licensing capabilities.</p>\n<h2>The winner: Nvidia</h2>\n<p>Both chipmakers are still great long-term growth plays. However, Nvidia clearly looks like the stronger investment than AMD right now -- even though it trades at significantly higher valuations.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Better Semiconductor Stock: Nvidia or AMD</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBetter Semiconductor Stock: Nvidia or AMD\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-29 11:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/28/better-semiconductor-stock-nvidia-or-amd/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nNvidia is profiting from the robust demand for GPUs in the gaming and data center markets.\nAMD is selling more CPUs for the PC and server markets as Intel tries to resolve its R&D and ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/28/better-semiconductor-stock-nvidia-or-amd/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4141":"半导体产品","AMD":"美国超微公司","BK4503":"景林资产持仓","BK4549":"软银资本持仓","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","BK4554":"元宇宙及AR概念","BK4551":"寇图资本持仓","NVDA":"英伟达","BK4548":"巴美列捷福持仓","BK4512":"苹果概念","BK4527":"明星科技股","BK4543":"AI","BK4567":"ESG概念","BK4534":"瑞士信贷持仓","BK4529":"IDC概念","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4550":"红杉资本持仓"},"source_url":"https://www.fool.com/investing/2021/11/28/better-semiconductor-stock-nvidia-or-amd/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2186262293","content_text":"Key Points\n\nNvidia is profiting from the robust demand for GPUs in the gaming and data center markets.\nAMD is selling more CPUs for the PC and server markets as Intel tries to resolve its R&D and manufacturing issues.\nOne of these chipmakers has more catalysts than the other.\n\nLast December, I compared two of the market's hottest semiconductor stocks: Nvidia (NASDAQ:NVDA) and Advanced Micro Devices (NASDAQ:AMD).\nAt the time, I said AMD was a better buy than Nvidia because I believed it was better insulated from macro headwinds, it would benefit from the arrivals of the new PlayStation 5 and Xbox Series consoles, and it would continue to grow its market share against Intel (NASDAQ:INTC).\nHowever, Nvidia's stock price has rallied nearly 150% since I wrote that article, while AMD's stock has only advanced about 70%. Let's take a fresh look at both chipmakers to see if I made the wrong call last year.\nIMAGE SOURCE: GETTY IMAGES.\nWhat I got wrong about Nvidia\nI had expected Nvidia's gaming and data center GPU businesses, which both experienced strong growth during the pandemic, to lose their momentum as the pandemic passed, people played fewer games, and data centers faced less pressure to upgrade their AI-processing servers. But that slowdown never happened.\nNvidia's revenue rose 53% to $16.7 billion in fiscal 2021, which ended back in January. That growth was led by its gaming and data center businesses, which easily offset the slower growth of its auto, professional visualization, and OEM businesses. Its adjusted gross margin expanded 310 basis points to 65.6%, while its adjusted net income surged 75% to $6.3 billion.\nIn the first nine months of fiscal 2022, Nvidia's revenue grew 65% year over year to $19.3 billion. Its gaming and data center businesses continued to grow, while its auto, professional visualization, and OEM segments all recovered as the pandemic-related headwinds waned. Its data center business also benefited from its takeover of the data center networking equipment maker Mellanox last April. Its adjusted gross margin rose 90 basis points year over year to 66.6%, and its adjusted net income jumped 83% to $7.9 billion.\nAnalysts expect Nvidia's revenue and earnings to grow 60% and 74%, respectively, for the full year. Those estimates notably don't factor in the potential success or failure of its $40 billion takeover bid for Arm Holdings from Softbank, which could be stuck in regulatory limbo for the foreseeable future.\nWhat I got wrong about AMD\nAMD performed very well over the past year, but it didn't actually gain much ground against Intel in the CPU market. Between the fourth quarters of 2020 and 2021, Intel's market share rose from 61.5% to 62.1%, according to PassMark, while AMD's share dipped from 38.5% to 37.8%.\nAMD's share of the discrete GPU market also dipped from 20% to 17% between the third quarters of 2020 and 2021, according to JPR. Nvidia's share rose from 80% to 83%. AMD benefited from robust sales of Sony and Microsoft's new gaming consoles this year, but the ongoing supply chain shortages are capping those gains.\nYet AMD continues to grow. Last year, its revenue rose 45% to $9.76 billion, Its adjusted gross margin expanded two percentage points to 45%, and its adjusted net income more than doubled to $1.58 billion.\nIn the first nine months of 2021, its revenue grew 78% year-over-year to $11.6 billion, its adjusted gross margin rose from 44% to 47%, and its adjusted net income soared 146% to $2.31 billion. It attributed most of that growth to robust sales of its Ryzen CPUs for PCs and Epyc CPUs for servers.\nAnalysts expect AMD's revenue and adjusted earnings to increase 65% and 104%, respectively, for the full year. Those estimates don't include its planned purchase of Xilinx (NASDAQ:XLNX), which will complement its Eypc data center business with programmable chips.\nThe valuations and upcoming challenges\nNvidia trades at 62 times forward earnings, while AMD has a lower forward price-to-earnings ratio of 46. Analysts expect both chipmakers to generate slower growth next year, but Nvidia might have more catalysts than AMD.\nNvidia's core GPU business remains far ahead of AMD's, and the secular strength of the gaming and data center markets -- along with the recovery of its smaller end markets -- should support its long-term growth.\nAMD is still a thorn in Intel's side, and it remains ahead of its larger CPU rival in the \"process race\" to create smaller and more advanced chips because it outsources its production to Taiwan Semiconductor Manufacturing (NYSE:TSM). However, that balance could eventually shift as Intel doubles down on its own first-party manufacturing efforts and tries to catch up to TSMC.\nThat looming threat, along with intense competition from Nvidia in the GPU market, could be preventing investors from paying a higher premium for AMD's stock, even though it's growing at a comparable rate as Nvidia.\nAMD's planned takeover of Xilinx, which mirrors Intel's takeover of Altera six years ago, is also arguably more important to its long-term growth plans than Nvidia's planned purchase of Arm -- which would merely complement its existing business with new CPU design and licensing capabilities.\nThe winner: Nvidia\nBoth chipmakers are still great long-term growth plays. However, Nvidia clearly looks like the stronger investment than AMD right now -- even though it trades at significantly higher valuations.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1003,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":872701641,"gmtCreate":1637569518835,"gmtModify":1637569518835,"author":{"id":"4100520219096230","authorId":"4100520219096230","name":"Piret","avatar":"https://static.tigerbbs.com/32af1c6079ca483ba4808b65db688b5e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100520219096230","authorIdStr":"4100520219096230"},"themes":[],"htmlText":"Like plsThank you","listText":"Like plsThank you","text":"Like plsThank you","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/872701641","repostId":"2185295758","repostType":4,"repost":{"id":"2185295758","kind":"highlight","pubTimestamp":1637536143,"share":"https://www.laohu8.com/m/news/2185295758?lang=&edition=full","pubTime":"2021-11-22 07:09","market":"us","language":"en","title":"Here's what history says about stock-market performance during the Thanksgiving week","url":"https://stock-news.laohu8.com/highlight/detail?id=2185295758","media":"MarketWatch","summary":"Will it be gobble, gobble for U.S. stock-market investors during the Thanksgiving week or an overdos","content":"<p>Will it be gobble, gobble for U.S. stock-market investors during the Thanksgiving week or an overdose of tryptophan?</p>\n<p>That’s the question that some may be considering as Wall Street completes the last full week of trading in November and gears up for a holiday period that is typically characterized by some of the lowest volumes of the year.</p>\n<p>U.S. financial markets are closed on Thursday, Nov. 26 for the Thanksgiving holiday and beyond Thursday’s closure, since 1992, stock exchanges have adhered to an abbreviated trading schedule the Friday after Thanksgiving in the U.S.</p>\n<p>The New York Stock Exchange and the Nasdaq will close at 1 p.m. Eastern time on Friday, while the Securities Industry and Financial Markets Association recommends a 2 p.m. Eastern close for U.S. bond markets.</p>\n<p>Against that backdrop, Thanksgiving has become synonymous with low-volume trading, which can sometimes lead to choppy action.</p>\n<p>So how has the market performed in this scenerio? Not bad?</p>\n<p>The folks at Bespoke Investment Group say that Thanksgiving week has lent itself to a modest gain for stocks dating back to 1945.</p>\n<p>The researchers say that since that point, “the entire week of Thanksgiving has averaged a 60 basis points, or 0.60 percentage point, advance for the S&amp;P 500,with the best returns coming on Wednesday before the holiday and Black Friday, and the only decline on average on Monday, the start of the week.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/9898cb0063474d1f44e9939d67ff509f\" tg-width=\"699\" tg-height=\"406\" width=\"100%\" height=\"auto\"><span>BESPOKE INVESTMENT GROUP</span></p>\n<p>Bespoke, however, says that more recently, gains have shifted to Mondays in Thanksgiving week, with small declines on Tuesday and rallies on the last two days of the session.</p>\n<p>The prospects of gains may be heartening to investors considering the prospect of inflation fears and uncertainty about the leadership of the Federal Reserve, with President Biden expected to decide whether to extend Jerome Powell’s tenure as Fed chairman, which ends in Feburary or possible turn to Fed Gov. Lael Brainard.</p>\n<p>Markets closed mostly lower on the Friday before Thanksgiving, with the S&amp;P 500&nbsp;booking a gain of 0.4%, the Nasdaq Composite&nbsp;posting a weekly gain of 1.2% and the Dow Jones Industrial Average&nbsp;closing ending lower for a second week in a row, off 1.4%.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's what history says about stock-market performance during the Thanksgiving week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's what history says about stock-market performance during the Thanksgiving week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-22 07:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/heres-what-history-says-about-stock-market-performance-during-the-thanksgiving-week-11637356248?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Will it be gobble, gobble for U.S. stock-market investors during the Thanksgiving week or an overdose of tryptophan?\nThat’s the question that some may be considering as Wall Street completes the last ...</p>\n\n<a href=\"https://www.marketwatch.com/story/heres-what-history-says-about-stock-market-performance-during-the-thanksgiving-week-11637356248?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"source_url":"https://www.marketwatch.com/story/heres-what-history-says-about-stock-market-performance-during-the-thanksgiving-week-11637356248?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2185295758","content_text":"Will it be gobble, gobble for U.S. stock-market investors during the Thanksgiving week or an overdose of tryptophan?\nThat’s the question that some may be considering as Wall Street completes the last full week of trading in November and gears up for a holiday period that is typically characterized by some of the lowest volumes of the year.\nU.S. financial markets are closed on Thursday, Nov. 26 for the Thanksgiving holiday and beyond Thursday’s closure, since 1992, stock exchanges have adhered to an abbreviated trading schedule the Friday after Thanksgiving in the U.S.\nThe New York Stock Exchange and the Nasdaq will close at 1 p.m. Eastern time on Friday, while the Securities Industry and Financial Markets Association recommends a 2 p.m. Eastern close for U.S. bond markets.\nAgainst that backdrop, Thanksgiving has become synonymous with low-volume trading, which can sometimes lead to choppy action.\nSo how has the market performed in this scenerio? Not bad?\nThe folks at Bespoke Investment Group say that Thanksgiving week has lent itself to a modest gain for stocks dating back to 1945.\nThe researchers say that since that point, “the entire week of Thanksgiving has averaged a 60 basis points, or 0.60 percentage point, advance for the S&P 500,with the best returns coming on Wednesday before the holiday and Black Friday, and the only decline on average on Monday, the start of the week.\nBESPOKE INVESTMENT GROUP\nBespoke, however, says that more recently, gains have shifted to Mondays in Thanksgiving week, with small declines on Tuesday and rallies on the last two days of the session.\nThe prospects of gains may be heartening to investors considering the prospect of inflation fears and uncertainty about the leadership of the Federal Reserve, with President Biden expected to decide whether to extend Jerome Powell’s tenure as Fed chairman, which ends in Feburary or possible turn to Fed Gov. Lael Brainard.\nMarkets closed mostly lower on the Friday before Thanksgiving, with the S&P 500 booking a gain of 0.4%, the Nasdaq Composite posting a weekly gain of 1.2% and the Dow Jones Industrial Average closing ending lower for a second week in a row, off 1.4%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":986,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":607173423,"gmtCreate":1639517935662,"gmtModify":1639517935782,"author":{"id":"4100520219096230","authorId":"4100520219096230","name":"Piret","avatar":"https://static.tigerbbs.com/32af1c6079ca483ba4808b65db688b5e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100520219096230","authorIdStr":"4100520219096230"},"themes":[],"htmlText":"Okay&nbsp;","listText":"Okay&nbsp;","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607173423","repostId":"2191930972","repostType":4,"repost":{"id":"2191930972","kind":"highlight","pubTimestamp":1639489168,"share":"https://www.laohu8.com/m/news/2191930972?lang=&edition=full","pubTime":"2021-12-14 21:39","market":"us","language":"en","title":"2 Warren Buffett Dividend Stocks to Buy Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2191930972","media":"Motley Fool","summary":"AbbVie and Royalty Pharma should be on every dividend investor's radar right now.","content":"<p><b>Berkshire Hathaway</b> (NYSE:BRK.A) (NYSE:BRK.B) CEO Warren Buffett is perhaps the best-known value investor of all time. Buffett's concept of value centers around the idea of a deep competitive moat, a sustainable business model, and strong free cash flows.</p>\n<p>As a result, most of Berkshire's top holdings over the past several decades have been well-established companies that offer top-notch shareholder rewards (share repurchases and dividends). Dividends have been particularly important to Berkshire's and Buffett's outstanding gains over the years, as dividends can be used to generate compounding returns when they are reinvested.</p>\n<p>Which Warren Buffett dividend stock picks are the most appealing buys right now? The healthcare stocks <b>AbbVie</b> (NYSE:ABBV) and <b>Royalty Pharma</b> (NASDAQ:RPRX) are two intriguing Berkshire holdings that each pay a respectable dividend. Although these two healthcare stocks are a tad riskier than the average Berkshire investment, there is a solid bull case for both AbbVie and Royalty Pharma right now. Read on to find out more about these two Warren Buffett dividend stock picks.</p>\n<h2>AbbVie: A high-yield growth stock</h2>\n<p>Berkshire first bought AbbVie during the third quarter of 2020. Although Buffett's diversified holding company has since pared back its position in the Illinois-based drugmaker, AbbVie's shares are still a worthwhile buy for most income investors. AbbVie's stock is an appealing income play for three clear-cut reasons. First, the drugmaker pays out a handsome 4.5% dividend yield on an annualized basis. That's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the highest yields among major drug manufacturers.</p>\n<p>Second, AbbVie is a Dividend Aristocrat, meaning that it has a strong track record of raising its dividend on a regular basis. In fact, the company has boosted its yield by a whopping 225% since 2013.</p>\n<p>Lastly, AbbVie has radically transformed its product portfolio ahead of the patent expiration for the flagship anti-inflammatory medicine Humira. The company now has two new high growth immunology assets with Skyrizi and Rinvoq, a strong and growing eye care franchise, several healthy avenues to explore for the commercial expansion of its Allergan aesthetics segment, an underappreciated migraine franchise, and two top-notch oncology drugs with Imbruvica and Venclexta.</p>\n<p>The net result is that AbbVie's top line is forecast to rise by a respectable 6.6% in 2022, despite biosimilar competition for Humira.</p>\n<h2>Royalty Pharma: A dependable revenue stream</h2>\n<p>Royalty Pharma is a brand new addition to the Berkshire family of holdings. The diversified holding company jumped into this pharma stock in the third quarter of 2021 following a sharp pullback in its share price. The backstory is that Royalty went public in the middle of 2020 and initially became a big hit with investors. The company's shares, however, have since reversed course due to the raging political debate over prescription drug prices in the U.S., as well as the negative sentiment toward biopharma stocks in general this year.</p>\n<p><img src=\"https://static.tigerbbs.com/a320f51af9bb7ac0d6359af7ed64161a\" tg-width=\"720\" tg-height=\"449\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>RPRX data by YCharts</p>\n<p>Why is Royalty's stock a bargain at these levels? Although Royalty pays out a less-than-stellar 1.78% annualized dividend yield, the company sports a rock-solid business model. Royalty Pharma makes money by funding late-stage clinical assets in exchange for a share of future revenues. The reason this business model is attractive is because it largely eliminates the risk of investing in either early stage drugmakers or biopharmas with aging portfolios. Royalty, in effect, can cherry-pick the best new growth assets to fund, without having to deal with early to mid-stage clinical setbacks or steep drop-offs in revenue from patent expirations.</p>\n<p>Now, Royalty's dividend yield isn't going to make you rich, but it is a source of reliable income. And that high level of dependability is arguably worth the price of admission alone.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Warren Buffett Dividend Stocks to Buy Right Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Warren Buffett Dividend Stocks to Buy Right Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-14 21:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/14/2-warren-buffett-dividend-stocks-to-buy-right-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Berkshire Hathaway (NYSE:BRK.A) (NYSE:BRK.B) CEO Warren Buffett is perhaps the best-known value investor of all time. Buffett's concept of value centers around the idea of a deep competitive moat, a ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/14/2-warren-buffett-dividend-stocks-to-buy-right-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BRK.A":"伯克希尔","ABBV":"艾伯维公司","BK4533":"AQR资本管理(全球第二大对冲基金)","BRK.B":"伯克希尔B","BK4566":"资本集团","BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","BK4176":"多领域控股","BK4139":"生物科技","RPRX":"Royalty Pharma plc","BK4550":"红杉资本持仓","BK4007":"制药"},"source_url":"https://www.fool.com/investing/2021/12/14/2-warren-buffett-dividend-stocks-to-buy-right-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2191930972","content_text":"Berkshire Hathaway (NYSE:BRK.A) (NYSE:BRK.B) CEO Warren Buffett is perhaps the best-known value investor of all time. Buffett's concept of value centers around the idea of a deep competitive moat, a sustainable business model, and strong free cash flows.\nAs a result, most of Berkshire's top holdings over the past several decades have been well-established companies that offer top-notch shareholder rewards (share repurchases and dividends). Dividends have been particularly important to Berkshire's and Buffett's outstanding gains over the years, as dividends can be used to generate compounding returns when they are reinvested.\nWhich Warren Buffett dividend stock picks are the most appealing buys right now? The healthcare stocks AbbVie (NYSE:ABBV) and Royalty Pharma (NASDAQ:RPRX) are two intriguing Berkshire holdings that each pay a respectable dividend. Although these two healthcare stocks are a tad riskier than the average Berkshire investment, there is a solid bull case for both AbbVie and Royalty Pharma right now. Read on to find out more about these two Warren Buffett dividend stock picks.\nAbbVie: A high-yield growth stock\nBerkshire first bought AbbVie during the third quarter of 2020. Although Buffett's diversified holding company has since pared back its position in the Illinois-based drugmaker, AbbVie's shares are still a worthwhile buy for most income investors. AbbVie's stock is an appealing income play for three clear-cut reasons. First, the drugmaker pays out a handsome 4.5% dividend yield on an annualized basis. That's one of the highest yields among major drug manufacturers.\nSecond, AbbVie is a Dividend Aristocrat, meaning that it has a strong track record of raising its dividend on a regular basis. In fact, the company has boosted its yield by a whopping 225% since 2013.\nLastly, AbbVie has radically transformed its product portfolio ahead of the patent expiration for the flagship anti-inflammatory medicine Humira. The company now has two new high growth immunology assets with Skyrizi and Rinvoq, a strong and growing eye care franchise, several healthy avenues to explore for the commercial expansion of its Allergan aesthetics segment, an underappreciated migraine franchise, and two top-notch oncology drugs with Imbruvica and Venclexta.\nThe net result is that AbbVie's top line is forecast to rise by a respectable 6.6% in 2022, despite biosimilar competition for Humira.\nRoyalty Pharma: A dependable revenue stream\nRoyalty Pharma is a brand new addition to the Berkshire family of holdings. The diversified holding company jumped into this pharma stock in the third quarter of 2021 following a sharp pullback in its share price. The backstory is that Royalty went public in the middle of 2020 and initially became a big hit with investors. The company's shares, however, have since reversed course due to the raging political debate over prescription drug prices in the U.S., as well as the negative sentiment toward biopharma stocks in general this year.\n\nRPRX data by YCharts\nWhy is Royalty's stock a bargain at these levels? Although Royalty pays out a less-than-stellar 1.78% annualized dividend yield, the company sports a rock-solid business model. Royalty Pharma makes money by funding late-stage clinical assets in exchange for a share of future revenues. The reason this business model is attractive is because it largely eliminates the risk of investing in either early stage drugmakers or biopharmas with aging portfolios. Royalty, in effect, can cherry-pick the best new growth assets to fund, without having to deal with early to mid-stage clinical setbacks or steep drop-offs in revenue from patent expirations.\nNow, Royalty's dividend yield isn't going to make you rich, but it is a source of reliable income. And that high level of dependability is arguably worth the price of admission alone.","news_type":1},"isVote":1,"tweetType":1,"viewCount":805,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605237566,"gmtCreate":1639179735850,"gmtModify":1639179735956,"author":{"id":"4100520219096230","authorId":"4100520219096230","name":"Piret","avatar":"https://static.tigerbbs.com/32af1c6079ca483ba4808b65db688b5e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100520219096230","authorIdStr":"4100520219096230"},"themes":[],"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605237566","repostId":"1199826178","repostType":4,"repost":{"id":"1199826178","kind":"news","pubTimestamp":1639149380,"share":"https://www.laohu8.com/m/news/1199826178?lang=&edition=full","pubTime":"2021-12-10 23:16","market":"us","language":"en","title":"Hedge Funds Ensnared in Expansive DOJ Probe Into Short Selling","url":"https://stock-news.laohu8.com/highlight/detail?id=1199826178","media":"Bloomberg","summary":"Funds and researchers are scrutinized by Justice Department. Inquiry seeks information on trading in several dozen stocks. The U.S. Justice Department has launched an expansive criminal investigation into short selling by hedge funds and research firms, scrutinizing their symbiotic relationships and hunting for signs that they improperly coordinated trades or broke other laws to profit, according to people familiar with the matter.The probe, run by the department’s fraud section with federal pro","content":"<ul>\n <li>Funds and researchers are scrutinized by Justice Department</li>\n <li>Inquiry seeks information on trading in several dozen stocks</li>\n</ul>\n<p>The U.S. Justice Department has launched an expansive criminal investigation into short selling by hedge funds and research firms, scrutinizing their symbiotic relationships and hunting for signs that they improperly coordinated trades or broke other laws to profit, according to people familiar with the matter.</p>\n<p>The probe, run by the department’s fraud section with federal prosecutors in Los Angeles, is digging into how hedge funds tap into research and set up their bets, especially in the run-up to publication of reports that move stocks.</p>\n<p>Authorities are prying into financial relationships between hedge funds and researchers, and hunting for signs that money managers sought to engineer startling stock drops or engaged in other abuses, such as insider trading, said two of the people, asking not to be named because the inquiries are confidential.</p>\n<p>Underscoring the inquiry’s sweep, federal investigators are examining trading in at least several dozen stocks, including well-known short targets such as&nbsp;Luckin Coffee Inc.,Banc of California Inc.,Mallinckrodt Plc&nbsp;and&nbsp;GSX Techedu Inc.And they’re scrutinizing the involvement of about a dozen or more firms -- though it’s not clear which ones, if any, may emerge as targets of the probe. Toronto-based&nbsp;Anson Funds&nbsp;and anonymous researcher Marcus Aurelius Value are among firms involved in the inquiry, the people said. Other prominent firms that circulated research on stocks under scrutiny include Carson Block’s Muddy Waters Capital and Andrew Left’s Citron Research.</p>\n<p>The U.S. probe opens yet another front in an already treacherous era for those who try to profit on stock drops. Some bearish funds&nbsp;threw in the towel&nbsp;as government stimulus buoyed prices during the pandemic. That pressure intensified as retail investors organized counterattacks on popular short targets, bidding up shares to inflictlosseson hedge funds this year. By late January, Citron vowed to give up short-selling research and focus on long bets.</p>\n<p>Meanwhile, companies criticized by short sellers have become increasingly bold in firing back, sometimes launching legal battles even as they face government probes that ultimately support short sellers’ theses. A number of corporate executives have been hoping U.S. authorities might help to further shift the focus to investors’ tactics.</p>\n<p>Still, successfully bringing charges against short sellers could be challenging, given that betting against companies and publishing research believed to be accurate is lawful and even beneficial for markets. So far, nobody has been accused of wrongdoing, and authorities may ultimately decide not to pursue charges.</p>\n<p>Government attorneys are trying to determine whether short sellers engaged in some form of deception -- say, by misleading the public about their financing of what appears to be independent research, violating confidentiality agreements with authors, or orchestrating stock plunges to panic shareholders and exacerbate selling.</p>\n<p>Spokespeople for the Justice Department and Muddy Waters declined to comment, and there was no response to messages sent to Anson Funds and Aurelius.</p>\n<p>An attorney for Citron said he’s aware of an industry probe but that it’s routine for U.S. investigators to open and close cases. He expressed doubt that their theories would be borne out.</p>\n<p>“Citron Capital&nbsp;and Mr. Left are successful because they do quality research and keep their reports secret from other short sellers until publication,” said the lawyer, James Spertus. “There is simply no truth behind any theory that short sellers coordinate amongst themselves before publishing reports, at least in regard to publications by Citron Capital and Andrew Left. I am hopeful that anyone investigating the issue will reach that conclusion as soon as possible.”</p>\n<p><b>Funding Research</b></p>\n<p>Hedge funds are known to strike a wide variety of deals with researchers, sometimes paying handsome subscription fees for fresh insights into possible corporate trouble, or even becoming an author’s primary source of funding. In one example, prominent financial investigator Harry Markopolos, who normally makes money from whistle-blower awards,said&nbsp;he partnered with a hedge fund to share profits when he released a report on&nbsp;General Electric Co.</p>\n<p>Some hedge funds have been known to suggest targets to researchers, who then deliver scathing reports.</p>\n<p>One cautionary tale emerged in court after Dallas-based&nbsp;Sabrepoint Capital&nbsp;agreed to pay a short-selling researcher a monthly retainer of $9,500 in 2018. Sabrepoint encouraged him to dig into real estate company&nbsp;Farmland Partners Inc.The researcher, who also wrote publicly under a pseudonym, later published an article on Seeking Alpha, setting off a 39% drop in Farmland’s share price. The company sued and used a judge’s order to force him to reveal his identity: Quinton Mathews.</p>\n<p>Mathews later said in a statement that he subsequently learned his article “contained inaccuracies and false allegations” and retracted it. He and Farmland reached a settlement. Sabrepoint has said it didn’t know about the Seeking Alpha article.</p>\n<p>Farmland also is on the list of stocks that the Justice Department is examining. Lawyers for Sabrepoint and Mathews declined to comment.</p>\n<p>The Justice Department unit handling the inquiry already has a formidable reputation on Wall Street. It recently brought several cases against global banks and traders for illegal spoofing of precious metals and Treasury futures. As part of that probe,JPMorgan Chase &amp; Co.&nbsp;paid more than $900 million in penalties after its traders placed and canceled orders for commodities to benefit positions held by the bank or prized hedge fund clients. Those cases were brought by analyzing trading data for suspicious patterns and then attributing it to individual traders.</p>\n<p>While prosecutors in the short-selling investigation issued subpoenas as recently as October, the effort has been underway much longer, the people said.</p>\n<p>The inquiry gained momentum after U.S. lawmakers called for more scrutiny of short sellers following the so-called meme-stock trading frenzy that erupted in January. In a single week that month, retail investors sent the price of&nbsp;GameStop Corp.&nbsp;soaring more than 700% before brokerages began limiting bets. Some organizers of the buying spree claimed hedge funds had been unfairly using their market clout to drive down stocks.</p>\n<p>Lawmakers have since held multiple hearings on the fracas, at times discussing whether to force short sellers to boost disclosures.</p>\n<p>Concerns about how short sellers carry out attacks have arisen repeatedly over the years.</p>\n<p>The Securities and Exchange Commission and Justice Department have gone after hedge funds for running “short and distort” campaigns. The practice typically involves setting up bearish bets, then releasing misleading or inaccurate information about a company to drive down the price before closing out the position for a profit.</p>\n<p>But there are also concerns about the impact that earnest research can have when it’s sprung by surprise on the market.</p>\n<p>Studies by Columbia University law professor Joshua Mitts have found that short sellers’ reports can briefly induce bouts of panic selling before shares rebound. In those jittery moments -- sometimes mere minutes or hours -- well-positioned short sellers can cash out of trades and pocket significant gains.</p>\n<p>Mitts examined more than 1,700 reports made by pseudonymous short sellers from 2010 to 2017, concluding that they contributed to more than $20 billion in dislocated values or temporarily mispriced stocks.</p>\n<p>Academics have been encouraging U.S. authorities to address the possibility that short sellers are laying out their cases against stocks, then using the impact of that news to quickly reap gains and quietly move on.</p>\n<p>Early last year, Mitts and about a dozen other prominent securities-law professors urged the SEC to write rules requiring that short sellers who voluntarily reveal bets against a stock be required to disclose when they’ve exited the position. The professors also asked the regulator to write a new rule that would make closing a short position immediately after disseminating a negative report -- with an intent to do so upon publication -- constitute market manipulation.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hedge Funds Ensnared in Expansive DOJ Probe Into Short Selling</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHedge Funds Ensnared in Expansive DOJ Probe Into Short Selling\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-10 23:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2021-12-10/hedge-funds-ensnared-in-expansive-doj-probe-into-short-selling?srnd=markets-vp><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Funds and researchers are scrutinized by Justice Department\nInquiry seeks information on trading in several dozen stocks\n\nThe U.S. Justice Department has launched an expansive criminal investigation ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-12-10/hedge-funds-ensnared-in-expansive-doj-probe-into-short-selling?srnd=markets-vp\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite","GE":"GE航空航天","BANC":"BANC OF CALIFORNIA","FPI":"Farmland Partners Inc","GME":"游戏驿站","MNKKQ":"Mallinckrodt plc.",".SPX":"S&P 500 Index","LKNCY":"瑞幸咖啡","GOTU":"高途",".DJI":"道琼斯"},"source_url":"https://www.bloomberg.com/news/articles/2021-12-10/hedge-funds-ensnared-in-expansive-doj-probe-into-short-selling?srnd=markets-vp","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1199826178","content_text":"Funds and researchers are scrutinized by Justice Department\nInquiry seeks information on trading in several dozen stocks\n\nThe U.S. Justice Department has launched an expansive criminal investigation into short selling by hedge funds and research firms, scrutinizing their symbiotic relationships and hunting for signs that they improperly coordinated trades or broke other laws to profit, according to people familiar with the matter.\nThe probe, run by the department’s fraud section with federal prosecutors in Los Angeles, is digging into how hedge funds tap into research and set up their bets, especially in the run-up to publication of reports that move stocks.\nAuthorities are prying into financial relationships between hedge funds and researchers, and hunting for signs that money managers sought to engineer startling stock drops or engaged in other abuses, such as insider trading, said two of the people, asking not to be named because the inquiries are confidential.\nUnderscoring the inquiry’s sweep, federal investigators are examining trading in at least several dozen stocks, including well-known short targets such as Luckin Coffee Inc.,Banc of California Inc.,Mallinckrodt Plc and GSX Techedu Inc.And they’re scrutinizing the involvement of about a dozen or more firms -- though it’s not clear which ones, if any, may emerge as targets of the probe. Toronto-based Anson Funds and anonymous researcher Marcus Aurelius Value are among firms involved in the inquiry, the people said. Other prominent firms that circulated research on stocks under scrutiny include Carson Block’s Muddy Waters Capital and Andrew Left’s Citron Research.\nThe U.S. probe opens yet another front in an already treacherous era for those who try to profit on stock drops. Some bearish funds threw in the towel as government stimulus buoyed prices during the pandemic. That pressure intensified as retail investors organized counterattacks on popular short targets, bidding up shares to inflictlosseson hedge funds this year. By late January, Citron vowed to give up short-selling research and focus on long bets.\nMeanwhile, companies criticized by short sellers have become increasingly bold in firing back, sometimes launching legal battles even as they face government probes that ultimately support short sellers’ theses. A number of corporate executives have been hoping U.S. authorities might help to further shift the focus to investors’ tactics.\nStill, successfully bringing charges against short sellers could be challenging, given that betting against companies and publishing research believed to be accurate is lawful and even beneficial for markets. So far, nobody has been accused of wrongdoing, and authorities may ultimately decide not to pursue charges.\nGovernment attorneys are trying to determine whether short sellers engaged in some form of deception -- say, by misleading the public about their financing of what appears to be independent research, violating confidentiality agreements with authors, or orchestrating stock plunges to panic shareholders and exacerbate selling.\nSpokespeople for the Justice Department and Muddy Waters declined to comment, and there was no response to messages sent to Anson Funds and Aurelius.\nAn attorney for Citron said he’s aware of an industry probe but that it’s routine for U.S. investigators to open and close cases. He expressed doubt that their theories would be borne out.\n“Citron Capital and Mr. Left are successful because they do quality research and keep their reports secret from other short sellers until publication,” said the lawyer, James Spertus. “There is simply no truth behind any theory that short sellers coordinate amongst themselves before publishing reports, at least in regard to publications by Citron Capital and Andrew Left. I am hopeful that anyone investigating the issue will reach that conclusion as soon as possible.”\nFunding Research\nHedge funds are known to strike a wide variety of deals with researchers, sometimes paying handsome subscription fees for fresh insights into possible corporate trouble, or even becoming an author’s primary source of funding. In one example, prominent financial investigator Harry Markopolos, who normally makes money from whistle-blower awards,said he partnered with a hedge fund to share profits when he released a report on General Electric Co.\nSome hedge funds have been known to suggest targets to researchers, who then deliver scathing reports.\nOne cautionary tale emerged in court after Dallas-based Sabrepoint Capital agreed to pay a short-selling researcher a monthly retainer of $9,500 in 2018. Sabrepoint encouraged him to dig into real estate company Farmland Partners Inc.The researcher, who also wrote publicly under a pseudonym, later published an article on Seeking Alpha, setting off a 39% drop in Farmland’s share price. The company sued and used a judge’s order to force him to reveal his identity: Quinton Mathews.\nMathews later said in a statement that he subsequently learned his article “contained inaccuracies and false allegations” and retracted it. He and Farmland reached a settlement. Sabrepoint has said it didn’t know about the Seeking Alpha article.\nFarmland also is on the list of stocks that the Justice Department is examining. Lawyers for Sabrepoint and Mathews declined to comment.\nThe Justice Department unit handling the inquiry already has a formidable reputation on Wall Street. It recently brought several cases against global banks and traders for illegal spoofing of precious metals and Treasury futures. As part of that probe,JPMorgan Chase & Co. paid more than $900 million in penalties after its traders placed and canceled orders for commodities to benefit positions held by the bank or prized hedge fund clients. Those cases were brought by analyzing trading data for suspicious patterns and then attributing it to individual traders.\nWhile prosecutors in the short-selling investigation issued subpoenas as recently as October, the effort has been underway much longer, the people said.\nThe inquiry gained momentum after U.S. lawmakers called for more scrutiny of short sellers following the so-called meme-stock trading frenzy that erupted in January. In a single week that month, retail investors sent the price of GameStop Corp. soaring more than 700% before brokerages began limiting bets. Some organizers of the buying spree claimed hedge funds had been unfairly using their market clout to drive down stocks.\nLawmakers have since held multiple hearings on the fracas, at times discussing whether to force short sellers to boost disclosures.\nConcerns about how short sellers carry out attacks have arisen repeatedly over the years.\nThe Securities and Exchange Commission and Justice Department have gone after hedge funds for running “short and distort” campaigns. The practice typically involves setting up bearish bets, then releasing misleading or inaccurate information about a company to drive down the price before closing out the position for a profit.\nBut there are also concerns about the impact that earnest research can have when it’s sprung by surprise on the market.\nStudies by Columbia University law professor Joshua Mitts have found that short sellers’ reports can briefly induce bouts of panic selling before shares rebound. In those jittery moments -- sometimes mere minutes or hours -- well-positioned short sellers can cash out of trades and pocket significant gains.\nMitts examined more than 1,700 reports made by pseudonymous short sellers from 2010 to 2017, concluding that they contributed to more than $20 billion in dislocated values or temporarily mispriced stocks.\nAcademics have been encouraging U.S. authorities to address the possibility that short sellers are laying out their cases against stocks, then using the impact of that news to quickly reap gains and quietly move on.\nEarly last year, Mitts and about a dozen other prominent securities-law professors urged the SEC to write rules requiring that short sellers who voluntarily reveal bets against a stock be required to disclose when they’ve exited the position. The professors also asked the regulator to write a new rule that would make closing a short position immediately after disseminating a negative report -- with an intent to do so upon publication -- constitute market manipulation.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1150,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696763788,"gmtCreate":1640772134268,"gmtModify":1640772134419,"author":{"id":"4100520219096230","authorId":"4100520219096230","name":"Piret","avatar":"https://static.tigerbbs.com/32af1c6079ca483ba4808b65db688b5e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100520219096230","authorIdStr":"4100520219096230"},"themes":[],"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696763788","repostId":"1147732268","repostType":4,"repost":{"id":"1147732268","kind":"news","pubTimestamp":1640743383,"share":"https://www.laohu8.com/m/news/1147732268?lang=&edition=full","pubTime":"2021-12-29 10:03","market":"us","language":"en","title":"TSLA Stock Price Predictions: Why These 2 Analysts Are Increasing Their Targets for Tesla in 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1147732268","media":"InvestorPlace","summary":"After opening higher by 1.4% on Tuesday, shares of Tesla(NASDAQ:TSLA) have taken a turn. TSLA stock ","content":"<p>After opening higher by 1.4% on Tuesday, shares of&nbsp;<b>Tesla</b>(NASDAQ:<b><u>TSLA</u></b>) have taken a turn. TSLA stock is down 0.5% today, despite a pair of analyst price-target hikes.&nbsp;However, if these price targets come to fruition, today’s action will be a distant memory.</p>\n<p><b>Argus Research</b>upped its target to $1,313 from $1,010.<b>Wedbush’s</b>&nbsp;Dan Ives also raised his price target, upping it to $1,400 from $1,100.</p>\n<p>Ives argues that&nbsp;Tesla’s China business&nbsp;could increase the stock price by another $400 per share in 2022. Furthermore, he estimates that Tesla will deliver between 1.4 million and 1.5 million vehicles next year. However, there could be even more upside.&nbsp;Ives has a bull-case price target of $1,800 per share. If achieved, it would represent about 66% upside in TSLA stock from current levels.</p>\n<p>According to Ives, “Musk &amp; Co. have navigated the chip supply shortages better than any automaker globally over the last six months, which is why Tesla is in a clear position of strength heading into 2022 with an inflection point year ahead.”</p>\n<p>Further, he says there are&nbsp;three main catalysts&nbsp;for a higher stock price this year: “By the end of 2022 Tesla will have the capacity for overall ~2 million units annually from roughly 1 million today … Austin has a clear path to launching its key flagship US factory (and HQ) in early 2022 … [Tesla can] further expand its auto [gross margins] and profitability profile over the next 12 to 18 months.”</p>\n<p>The latest analyst actions aren’t the only bullish calls this month.&nbsp;A few weeks ago, New Street analyst Pierre Ferraguincreased his price target&nbsp;from $1,298 to a Street-high $1,580. The bullish stance comes from high expectations for the company’s Shanghai plant, believing it will turnout 700,000 vehicles annually. Additionally, the analyst believes Tesla will surpass its delivery estimate of 266,000 units in the fourth quarter.</p>\n<p>TSLA Stock This Year</p>\n<p>So far for the year, TSLA stock is up about 53%. While that’s vastly better than&nbsp;<b>Nio</b>(NYSE:<b><u>NIO</u></b>) and several of the newcomers in the EV space, Tesla’s performance lags&nbsp;<b>Ford</b>(NYSE:<b><u>F</u></b>) and&nbsp;<b>Lucid Motors</b>(NASDAQ:<b><u>LCID</u></b>), which are up 137% and 275% on the year, respectively.</p>\n<p>While shares are down slightly on the day now, TSLA stock is still up more than 20% from last week’s low. The rally helped the company regain its $1 trillion market capitalization, by far the largest in the auto sector.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TSLA Stock Price Predictions: Why These 2 Analysts Are Increasing Their Targets for Tesla in 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTSLA Stock Price Predictions: Why These 2 Analysts Are Increasing Their Targets for Tesla in 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-29 10:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/tsla-stock-price-predictions-why-these-2-analysts-are-increasing-their-targets-for-tesla-in-2022/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After opening higher by 1.4% on Tuesday, shares of Tesla(NASDAQ:TSLA) have taken a turn. TSLA stock is down 0.5% today, despite a pair of analyst price-target hikes. However, if these price targets ...</p>\n\n<a href=\"https://investorplace.com/2021/12/tsla-stock-price-predictions-why-these-2-analysts-are-increasing-their-targets-for-tesla-in-2022/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"source_url":"https://investorplace.com/2021/12/tsla-stock-price-predictions-why-these-2-analysts-are-increasing-their-targets-for-tesla-in-2022/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147732268","content_text":"After opening higher by 1.4% on Tuesday, shares of Tesla(NASDAQ:TSLA) have taken a turn. TSLA stock is down 0.5% today, despite a pair of analyst price-target hikes. However, if these price targets come to fruition, today’s action will be a distant memory.\nArgus Researchupped its target to $1,313 from $1,010.Wedbush’s Dan Ives also raised his price target, upping it to $1,400 from $1,100.\nIves argues that Tesla’s China business could increase the stock price by another $400 per share in 2022. Furthermore, he estimates that Tesla will deliver between 1.4 million and 1.5 million vehicles next year. However, there could be even more upside. Ives has a bull-case price target of $1,800 per share. If achieved, it would represent about 66% upside in TSLA stock from current levels.\nAccording to Ives, “Musk & Co. have navigated the chip supply shortages better than any automaker globally over the last six months, which is why Tesla is in a clear position of strength heading into 2022 with an inflection point year ahead.”\nFurther, he says there are three main catalysts for a higher stock price this year: “By the end of 2022 Tesla will have the capacity for overall ~2 million units annually from roughly 1 million today … Austin has a clear path to launching its key flagship US factory (and HQ) in early 2022 … [Tesla can] further expand its auto [gross margins] and profitability profile over the next 12 to 18 months.”\nThe latest analyst actions aren’t the only bullish calls this month. A few weeks ago, New Street analyst Pierre Ferraguincreased his price target from $1,298 to a Street-high $1,580. The bullish stance comes from high expectations for the company’s Shanghai plant, believing it will turnout 700,000 vehicles annually. Additionally, the analyst believes Tesla will surpass its delivery estimate of 266,000 units in the fourth quarter.\nTSLA Stock This Year\nSo far for the year, TSLA stock is up about 53%. While that’s vastly better than Nio(NYSE:NIO) and several of the newcomers in the EV space, Tesla’s performance lags Ford(NYSE:F) and Lucid Motors(NASDAQ:LCID), which are up 137% and 275% on the year, respectively.\nWhile shares are down slightly on the day now, TSLA stock is still up more than 20% from last week’s low. The rally helped the company regain its $1 trillion market capitalization, by far the largest in the auto sector.","news_type":1},"isVote":1,"tweetType":1,"viewCount":993,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":699451526,"gmtCreate":1639880886508,"gmtModify":1639880886601,"author":{"id":"4100520219096230","authorId":"4100520219096230","name":"Piret","avatar":"https://static.tigerbbs.com/32af1c6079ca483ba4808b65db688b5e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100520219096230","authorIdStr":"4100520219096230"},"themes":[],"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/699451526","repostId":"1116106959","repostType":4,"repost":{"id":"1116106959","kind":"news","pubTimestamp":1639785552,"share":"https://www.laohu8.com/m/news/1116106959?lang=&edition=full","pubTime":"2021-12-18 07:59","market":"us","language":"en","title":"Wall Street ends down after mostly negative week","url":"https://stock-news.laohu8.com/highlight/detail?id=1116106959","media":"Reuters","summary":" - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.All three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.Nvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&P 500 and Nasdaq.The S","content":"<p>(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.</p>\n<p>All three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.</p>\n<p>Nvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&amp;P 500 and Nasdaq.</p>\n<p>The S&amp;P 500 growth index lost 0.7% and the value index declined 1.4%.</p>\n<p>All of the 11 major S&amp;P 500 sector indexes fell, with financials leading the way down with a 2.3% drop. Energy lost 2.2%.</p>\n<p>Adding to uncertainty, Pfizer said on Friday the pandemic could extend through next year. European countries geared up for further travel and social restrictions and a study warned that the rapidly spreading Omicron coronavirus variant was five times more likely to reinfect people than its predecessor, Delta.</p>\n<p>Traders also pointed to year-end tax selling and the simultaneous expiration of stock options, stock index futures and index options contracts - known as triple witching - as potential causes for volatility.</p>\n<p>\"It's a big options expiration day,\" said Joe Saluzzi, co-manager of trading at Themis Trading in Chatham, New Jersey. \"And now you draw on top of that some Omicron, and you've got volatility, and I think it creates a lot of uncertainty amongst investors. Where are you going to position for the end of the year?\"</p>\n<p>Heavyweight growth stocks including Nvidia and Microsoft have outperformed the broader market in 2021, while the Philadelphia SE Semiconductor index has surged about 35%. The benchmark S&amp;P 500 index gained around 23% in the same period.</p>\n<p>In Friday's session, the Dow Jones Industrial Average fell 1.48% to end at 35,365.44 points, while the S&amp;P 500 lost 1.03% to 4,620.64.</p>\n<p>The Nasdaq Composite dropped 0.07% to 15,169.68.</p>\n<p>On a positive note, the small-cap Russell 2000 index rallied 1% after having fallen more than 10% from a record high in early November.</p>\n<p>With options expiring, volume on U.S. exchanges jumped to 16.6 billion shares, far above the 11.9 billion average over the last 20 trading days.</p>\n<p>For the week, the S&amp;P 500 fell 1.9%, the Dow lost 1.7% and the Nasdaq declined 2.9%.</p>\n<p>In Friday's session, Oracle tumbled 6.4% after the Wall Street Journal reported the enterprise software maker is in talks to buy electronic medical records company Cerner in a deal that could be valued at $30 billion. Shares of Cerner surged 12.9%.</p>\n<p>FedEx Corp rose almost 5% after the delivery firm reinstated its original fiscal 2022 forecast on Thursday, even as persistent labor woes chipped away profits.</p>\n<p>Declining issues outnumbered advancing ones on the NYSE by a 1.50-to-1 ratio; on Nasdaq, a 1.16-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 22 new 52-week highs and seven new lows; the Nasdaq Composite recorded 28 new highs and 341 new lows.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street ends down after mostly negative week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street ends down after mostly negative week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-18 07:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-...</p>\n\n<a href=\"https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"source_url":"https://finance.yahoo.com/news/us-stocks-wall-street-ends-212015460.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116106959","content_text":"(Reuters) - Wall Street finished lower on Friday, weighed down by Big Tech as investors worried about the Omicron coronavirus variant and digested the Federal Reserve's decision to end its pandemic-era stimulus faster.\nAll three main U.S. stock indexes ended with a decline for the week after the Fed on Wednesday signaled three quarter-percentage-point interest rate hikes by the end of 2022 to combat surging inflation.\nNvidia dropped 2.1% and Alphabet lost 1.9%, both weighing on the S&P 500 and Nasdaq.\nThe S&P 500 growth index lost 0.7% and the value index declined 1.4%.\nAll of the 11 major S&P 500 sector indexes fell, with financials leading the way down with a 2.3% drop. Energy lost 2.2%.\nAdding to uncertainty, Pfizer said on Friday the pandemic could extend through next year. European countries geared up for further travel and social restrictions and a study warned that the rapidly spreading Omicron coronavirus variant was five times more likely to reinfect people than its predecessor, Delta.\nTraders also pointed to year-end tax selling and the simultaneous expiration of stock options, stock index futures and index options contracts - known as triple witching - as potential causes for volatility.\n\"It's a big options expiration day,\" said Joe Saluzzi, co-manager of trading at Themis Trading in Chatham, New Jersey. \"And now you draw on top of that some Omicron, and you've got volatility, and I think it creates a lot of uncertainty amongst investors. Where are you going to position for the end of the year?\"\nHeavyweight growth stocks including Nvidia and Microsoft have outperformed the broader market in 2021, while the Philadelphia SE Semiconductor index has surged about 35%. The benchmark S&P 500 index gained around 23% in the same period.\nIn Friday's session, the Dow Jones Industrial Average fell 1.48% to end at 35,365.44 points, while the S&P 500 lost 1.03% to 4,620.64.\nThe Nasdaq Composite dropped 0.07% to 15,169.68.\nOn a positive note, the small-cap Russell 2000 index rallied 1% after having fallen more than 10% from a record high in early November.\nWith options expiring, volume on U.S. exchanges jumped to 16.6 billion shares, far above the 11.9 billion average over the last 20 trading days.\nFor the week, the S&P 500 fell 1.9%, the Dow lost 1.7% and the Nasdaq declined 2.9%.\nIn Friday's session, Oracle tumbled 6.4% after the Wall Street Journal reported the enterprise software maker is in talks to buy electronic medical records company Cerner in a deal that could be valued at $30 billion. Shares of Cerner surged 12.9%.\nFedEx Corp rose almost 5% after the delivery firm reinstated its original fiscal 2022 forecast on Thursday, even as persistent labor woes chipped away profits.\nDeclining issues outnumbered advancing ones on the NYSE by a 1.50-to-1 ratio; on Nasdaq, a 1.16-to-1 ratio favored advancers.\nThe S&P 500 posted 22 new 52-week highs and seven new lows; the Nasdaq Composite recorded 28 new highs and 341 new lows.","news_type":1},"isVote":1,"tweetType":1,"viewCount":893,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606570499,"gmtCreate":1638912853402,"gmtModify":1638912853551,"author":{"id":"4100520219096230","authorId":"4100520219096230","name":"Piret","avatar":"https://static.tigerbbs.com/32af1c6079ca483ba4808b65db688b5e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100520219096230","authorIdStr":"4100520219096230"},"themes":[],"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606570499","repostId":"1102393012","repostType":4,"repost":{"id":"1102393012","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638882198,"share":"https://www.laohu8.com/m/news/1102393012?lang=&edition=full","pubTime":"2021-12-07 21:03","market":"us","language":"en","title":"Toplines Before US Market Open on Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1102393012","media":"Tiger Newspress","summary":"U.S. stocks looked set to open 1% higher on Tuesday as technology firms bounced back on easing conce","content":"<p>U.S. stocks looked set to open 1% higher on Tuesday as technology firms bounced back on easing concerns around the Omicron variant, while Intel jumped after plans to take its self-driving car unit public.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up 350 points, or 0.99%, S&amp;P 500 e-minis were up 59.75 points, or 1.30%, and Nasdaq 100 e-minis were up 286.25 points, or 1.81%.</p>\n<p><img src=\"https://static.tigerbbs.com/642e33917698c89931671b55c0e9420c\" tg-width=\"1080\" tg-height=\"400\" referrerpolicy=\"no-referrer\"></p>\n<p>Big Tech stocks Google-owner Alphabet,Microsoft, Amazon,Meta Platform&nbsp;and Apple&nbsp;gained nearly 2%.</p>\n<p>Travel shares continued the momentum, with Carnival Corp&nbsp;and United Airlines&nbsp;up 3.6% and 3.4%, respectively, leading the gains among the major airlines and cruise operators.</p>\n<p>Oil stocks including Exxon Mobil&nbsp;and Chevron Corp&nbsp;gained, tracking gains in crude prices.</p>\n<p><b>Stocks making the biggest moves premarket:</b></p>\n<p><b>Intel(INTC) </b>– The chip maker's shares surged 8% in premarket trading after it said it would take its Mobileye self-driving car unit public, planning a mid-2022 initial public offering. The Wall Street Journal had earlier reported those plans, saying an IPO could value Mobileye at more than $50 billion.Other chipmakers <b>Advanced Micro Devices</b><b>(AMD)</b>, <b>Micron Technology</b><b>(MU)</b>&nbsp;and <b>Nvidia</b><b>(NVDA)</b>&nbsp;rose about&nbsp;3%.</p>\n<p><b>Tesla(TSLA) </b>– Tesla is replacing faulty cameras on some of its models, according to internal documents seen by CNBC. The cameras can cause a driver to see a blank or choppy video on a car's primary display. Separately, UBS issued a report that said no rival would come close to Tesla in 2022, although it maintained a \"neutral\" rating on the stock. Tesla gained 3.1% in premarket action.</p>\n<p><b>GlaxoSmithKline(GSK)</b> – Glaxo said early-stage studies showed its antibody therapy for Covid-19 – developed in partnership with U.S.-based<b>&nbsp;Vir Biotechnology(VIR)</b> – is effective against the omicron variant. Vir jumped 6.9% in premarket trading, while Glaxo added 0.6%.</p>\n<p><b>American Airlines(AAL)</b> – Chief Executive Officer Doug Parker announced he would step down from that job on March 31 and remain as chairman. He'll be replaced as CEO by current American Airlines President Robert Isom. American rose 3.4% in the premarket.</p>\n<p><b>Coupa Software(COUP)</b> – The business software company earned an adjusted 31 cents per share for its latest quarter, well above the 2-cent consensus estimate, with revenue also topping forecasts. However, its loss widened from a year ago with a surge in operating expenses, and shares tumbled 8% in premarket trading.</p>\n<p><b>Bumble(BMBL)</b> – The dating service operator's shares rallied 6.8% in the premarket after J.P. Morgan Securities upgraded the stock to \"overweight\" from \"neutral\" following a meeting with management. The firm said it was now more confident in the growth trajectory and prospects for user engagement with the Bumble app.</p>\n<p><b>AutoZone(AZO)</b> – The auto parts retailer reported a quarterly profit of $25.69 per share, beating the consensus estimate of $20.87. Revenue also beat estimates, with comparable store sales jumping 13.6%. Analysts surveyed by StreetAccount had predicted a comp-store sales rise of 5%.</p>\n<p><b>Designer Brands(DBI)</b> – The footwear retailer beat estimates by 30 cents with adjusted quarterly earnings of 86 cents per share, but revenue fell short of Wall Street forecasts. Comparable store sales did surge by 40.8%, but that was less than the 44.5% analysts had anticipated. Nonetheless, shares rallied 7.4% in premarket trading.</p>\n<p><b>Constellation Brands(STZ) </b>– The brewer of Corona beer agreed to build a new brewery in southeastern Mexico, according to a Wall Street Journal report. The agreement – set to be announced as early as this week – comes two years after the government forced Constellation to close a nearly completed plant near the U.S.-Mexican border.</p>\n<p><b>Mimecast(MIME)</b> – The cybersecurity company agreed to be acquired by private equity firm Permira for $80 per share in cash, or about $5.8 billion. Mimecast jumped 6.7% in the premarket.</p>\n<p><b>MongoDB(MDB)</b> – MongoDB surged 21.4% in premarket action after the database platform company reported a smaller-than-expected quarterly loss and beat Street revenue forecasts. MongoDB also raised its financial outlook for the year on increased demand from businesses for online connectivity.</p>\n<p><b>Acadia Pharmaceuticals(ACAD) </b>– Acadia soared 17.3% in the premarket after announcing positive results in a late-stage trial of its experimental treatment for Rett Syndrome, a genetic disorder that primarily affects brain development in girls.</p>\n<p><b>Jack In The Box(JACK)</b> – Jack In The Box was upgraded to \"buy\" from \"hold\" at Deutsche Bank, which said the restaurant operator's acquisition of Mexican food chain&nbsp;Del Taco(TACO) makes sense. Jack In The Box shares had fallen more than 4% Monday after the deal was announced. Jack In The Box gained 1.6% in premarket trading.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Tuesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Tuesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-07 21:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S. stocks looked set to open 1% higher on Tuesday as technology firms bounced back on easing concerns around the Omicron variant, while Intel jumped after plans to take its self-driving car unit public.</p>\n<p>At 8:00 a.m. ET, Dow e-minis were up 350 points, or 0.99%, S&amp;P 500 e-minis were up 59.75 points, or 1.30%, and Nasdaq 100 e-minis were up 286.25 points, or 1.81%.</p>\n<p><img src=\"https://static.tigerbbs.com/642e33917698c89931671b55c0e9420c\" tg-width=\"1080\" tg-height=\"400\" referrerpolicy=\"no-referrer\"></p>\n<p>Big Tech stocks Google-owner Alphabet,Microsoft, Amazon,Meta Platform&nbsp;and Apple&nbsp;gained nearly 2%.</p>\n<p>Travel shares continued the momentum, with Carnival Corp&nbsp;and United Airlines&nbsp;up 3.6% and 3.4%, respectively, leading the gains among the major airlines and cruise operators.</p>\n<p>Oil stocks including Exxon Mobil&nbsp;and Chevron Corp&nbsp;gained, tracking gains in crude prices.</p>\n<p><b>Stocks making the biggest moves premarket:</b></p>\n<p><b>Intel(INTC) </b>– The chip maker's shares surged 8% in premarket trading after it said it would take its Mobileye self-driving car unit public, planning a mid-2022 initial public offering. The Wall Street Journal had earlier reported those plans, saying an IPO could value Mobileye at more than $50 billion.Other chipmakers <b>Advanced Micro Devices</b><b>(AMD)</b>, <b>Micron Technology</b><b>(MU)</b>&nbsp;and <b>Nvidia</b><b>(NVDA)</b>&nbsp;rose about&nbsp;3%.</p>\n<p><b>Tesla(TSLA) </b>– Tesla is replacing faulty cameras on some of its models, according to internal documents seen by CNBC. The cameras can cause a driver to see a blank or choppy video on a car's primary display. Separately, UBS issued a report that said no rival would come close to Tesla in 2022, although it maintained a \"neutral\" rating on the stock. Tesla gained 3.1% in premarket action.</p>\n<p><b>GlaxoSmithKline(GSK)</b> – Glaxo said early-stage studies showed its antibody therapy for Covid-19 – developed in partnership with U.S.-based<b>&nbsp;Vir Biotechnology(VIR)</b> – is effective against the omicron variant. Vir jumped 6.9% in premarket trading, while Glaxo added 0.6%.</p>\n<p><b>American Airlines(AAL)</b> – Chief Executive Officer Doug Parker announced he would step down from that job on March 31 and remain as chairman. He'll be replaced as CEO by current American Airlines President Robert Isom. American rose 3.4% in the premarket.</p>\n<p><b>Coupa Software(COUP)</b> – The business software company earned an adjusted 31 cents per share for its latest quarter, well above the 2-cent consensus estimate, with revenue also topping forecasts. However, its loss widened from a year ago with a surge in operating expenses, and shares tumbled 8% in premarket trading.</p>\n<p><b>Bumble(BMBL)</b> – The dating service operator's shares rallied 6.8% in the premarket after J.P. Morgan Securities upgraded the stock to \"overweight\" from \"neutral\" following a meeting with management. The firm said it was now more confident in the growth trajectory and prospects for user engagement with the Bumble app.</p>\n<p><b>AutoZone(AZO)</b> – The auto parts retailer reported a quarterly profit of $25.69 per share, beating the consensus estimate of $20.87. Revenue also beat estimates, with comparable store sales jumping 13.6%. Analysts surveyed by StreetAccount had predicted a comp-store sales rise of 5%.</p>\n<p><b>Designer Brands(DBI)</b> – The footwear retailer beat estimates by 30 cents with adjusted quarterly earnings of 86 cents per share, but revenue fell short of Wall Street forecasts. Comparable store sales did surge by 40.8%, but that was less than the 44.5% analysts had anticipated. Nonetheless, shares rallied 7.4% in premarket trading.</p>\n<p><b>Constellation Brands(STZ) </b>– The brewer of Corona beer agreed to build a new brewery in southeastern Mexico, according to a Wall Street Journal report. The agreement – set to be announced as early as this week – comes two years after the government forced Constellation to close a nearly completed plant near the U.S.-Mexican border.</p>\n<p><b>Mimecast(MIME)</b> – The cybersecurity company agreed to be acquired by private equity firm Permira for $80 per share in cash, or about $5.8 billion. Mimecast jumped 6.7% in the premarket.</p>\n<p><b>MongoDB(MDB)</b> – MongoDB surged 21.4% in premarket action after the database platform company reported a smaller-than-expected quarterly loss and beat Street revenue forecasts. MongoDB also raised its financial outlook for the year on increased demand from businesses for online connectivity.</p>\n<p><b>Acadia Pharmaceuticals(ACAD) </b>– Acadia soared 17.3% in the premarket after announcing positive results in a late-stage trial of its experimental treatment for Rett Syndrome, a genetic disorder that primarily affects brain development in girls.</p>\n<p><b>Jack In The Box(JACK)</b> – Jack In The Box was upgraded to \"buy\" from \"hold\" at Deutsche Bank, which said the restaurant operator's acquisition of Mexican food chain&nbsp;Del Taco(TACO) makes sense. Jack In The Box shares had fallen more than 4% Monday after the deal was announced. Jack In The Box gained 1.6% in premarket trading.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"COUP":"Coupa Software Inc","AZO":"汽车地带","STZ":"星座品牌","NVDA":"英伟达","MIME":"Mimecast Ltd","ACAD":"阿卡迪亚","BMBL":"Bumble Inc.","GSK":"葛兰素史克",".SPX":"S&P 500 Index","AMD":"美国超微公司","AAL":"美国航空","DBI":"Designer Brands Inc","MU":"美光科技","JACK":"Jack In The Box Inc","TSLA":"特斯拉","MDB":"MongoDB Inc.",".DJI":"道琼斯","INTC":"英特尔",".IXIC":"NASDAQ Composite"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102393012","content_text":"U.S. stocks looked set to open 1% higher on Tuesday as technology firms bounced back on easing concerns around the Omicron variant, while Intel jumped after plans to take its self-driving car unit public.\nAt 8:00 a.m. ET, Dow e-minis were up 350 points, or 0.99%, S&P 500 e-minis were up 59.75 points, or 1.30%, and Nasdaq 100 e-minis were up 286.25 points, or 1.81%.\n\nBig Tech stocks Google-owner Alphabet,Microsoft, Amazon,Meta Platform and Apple gained nearly 2%.\nTravel shares continued the momentum, with Carnival Corp and United Airlines up 3.6% and 3.4%, respectively, leading the gains among the major airlines and cruise operators.\nOil stocks including Exxon Mobil and Chevron Corp gained, tracking gains in crude prices.\nStocks making the biggest moves premarket:\nIntel(INTC) – The chip maker's shares surged 8% in premarket trading after it said it would take its Mobileye self-driving car unit public, planning a mid-2022 initial public offering. The Wall Street Journal had earlier reported those plans, saying an IPO could value Mobileye at more than $50 billion.Other chipmakers Advanced Micro Devices(AMD), Micron Technology(MU) and Nvidia(NVDA) rose about 3%.\nTesla(TSLA) – Tesla is replacing faulty cameras on some of its models, according to internal documents seen by CNBC. The cameras can cause a driver to see a blank or choppy video on a car's primary display. Separately, UBS issued a report that said no rival would come close to Tesla in 2022, although it maintained a \"neutral\" rating on the stock. Tesla gained 3.1% in premarket action.\nGlaxoSmithKline(GSK) – Glaxo said early-stage studies showed its antibody therapy for Covid-19 – developed in partnership with U.S.-based Vir Biotechnology(VIR) – is effective against the omicron variant. Vir jumped 6.9% in premarket trading, while Glaxo added 0.6%.\nAmerican Airlines(AAL) – Chief Executive Officer Doug Parker announced he would step down from that job on March 31 and remain as chairman. He'll be replaced as CEO by current American Airlines President Robert Isom. American rose 3.4% in the premarket.\nCoupa Software(COUP) – The business software company earned an adjusted 31 cents per share for its latest quarter, well above the 2-cent consensus estimate, with revenue also topping forecasts. However, its loss widened from a year ago with a surge in operating expenses, and shares tumbled 8% in premarket trading.\nBumble(BMBL) – The dating service operator's shares rallied 6.8% in the premarket after J.P. Morgan Securities upgraded the stock to \"overweight\" from \"neutral\" following a meeting with management. The firm said it was now more confident in the growth trajectory and prospects for user engagement with the Bumble app.\nAutoZone(AZO) – The auto parts retailer reported a quarterly profit of $25.69 per share, beating the consensus estimate of $20.87. Revenue also beat estimates, with comparable store sales jumping 13.6%. Analysts surveyed by StreetAccount had predicted a comp-store sales rise of 5%.\nDesigner Brands(DBI) – The footwear retailer beat estimates by 30 cents with adjusted quarterly earnings of 86 cents per share, but revenue fell short of Wall Street forecasts. Comparable store sales did surge by 40.8%, but that was less than the 44.5% analysts had anticipated. Nonetheless, shares rallied 7.4% in premarket trading.\nConstellation Brands(STZ) – The brewer of Corona beer agreed to build a new brewery in southeastern Mexico, according to a Wall Street Journal report. The agreement – set to be announced as early as this week – comes two years after the government forced Constellation to close a nearly completed plant near the U.S.-Mexican border.\nMimecast(MIME) – The cybersecurity company agreed to be acquired by private equity firm Permira for $80 per share in cash, or about $5.8 billion. Mimecast jumped 6.7% in the premarket.\nMongoDB(MDB) – MongoDB surged 21.4% in premarket action after the database platform company reported a smaller-than-expected quarterly loss and beat Street revenue forecasts. MongoDB also raised its financial outlook for the year on increased demand from businesses for online connectivity.\nAcadia Pharmaceuticals(ACAD) – Acadia soared 17.3% in the premarket after announcing positive results in a late-stage trial of its experimental treatment for Rett Syndrome, a genetic disorder that primarily affects brain development in girls.\nJack In The Box(JACK) – Jack In The Box was upgraded to \"buy\" from \"hold\" at Deutsche Bank, which said the restaurant operator's acquisition of Mexican food chain Del Taco(TACO) makes sense. Jack In The Box shares had fallen more than 4% Monday after the deal was announced. Jack In The Box gained 1.6% in premarket trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":888,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":604544303,"gmtCreate":1639431416598,"gmtModify":1639431416713,"author":{"id":"4100520219096230","authorId":"4100520219096230","name":"Piret","avatar":"https://static.tigerbbs.com/32af1c6079ca483ba4808b65db688b5e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100520219096230","authorIdStr":"4100520219096230"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/604544303","repostId":"1101330061","repostType":4,"isVote":1,"tweetType":1,"viewCount":894,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":606927618,"gmtCreate":1638825874594,"gmtModify":1638825874594,"author":{"id":"4100520219096230","authorId":"4100520219096230","name":"Piret","avatar":"https://static.tigerbbs.com/32af1c6079ca483ba4808b65db688b5e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4100520219096230","authorIdStr":"4100520219096230"},"themes":[],"htmlText":"Okay","listText":"Okay","text":"Okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606927618","repostId":"1163923112","repostType":4,"repost":{"id":"1163923112","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1638797491,"share":"https://www.laohu8.com/m/news/1163923112?lang=&edition=full","pubTime":"2021-12-06 21:31","market":"us","language":"en","title":"10 Biggest Price Target Changes For Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1163923112","media":"Benzinga","summary":"Cowen & Co. raised the price target on The Boston Beer Company, Inc.(NYSE:SAM) from $400 to $500. Bo","content":"<ul>\n <li>Cowen &amp; Co. raised the price target on&nbsp;<b>The Boston Beer Company, Inc.</b>(NYSE:SAM) from $400 to $500. Boston Beer shares rose 1% to $465.20 in pre-market trading.</li>\n <li>Keybanc lowered&nbsp;<b>Darden Restaurants, Inc.</b>(NYSE:DRI) price target from $180 to $172. Darden shares fell 0.5% to close at $142.35 on Friday.</li>\n <li>Barclays lifted&nbsp;<b>Ulta Beauty, Inc.</b>(NASDAQ:ULTA) price target from $492 to $516. Ulta Beauty shares rose 0.6% to $380.90 pre-market trading.</li>\n <li>Oppenheimer raised the price target on&nbsp;<b>Lowe's Companies, Inc.</b>(NYSE:LOW) from $235 to $300. Lowe's Companies shares rose 0.9% to $250.89 in pre-market trading.</li>\n <li>Telsey Advisory Group cut&nbsp;<b>Big Lots, Inc.</b>(NYSE:BIG) price target from $57 to $55. Big Lots shares rose 2.3% to $47.01 in pre-market trading.</li>\n <li>Morgan Stanley boosted the price target for&nbsp;<b>SVB Financial Group</b>(NASDAQ:SIVB) from $775 to $985. Morgan Stanley shares fell 5.3% to close at $674.57 on Friday.</li>\n <li>Goldman Sachs cut&nbsp;<b>Accel Entertainment, Inc.</b>(NYSE:ACEL) price target from $15.5 to $14.5. Accel Entertainment shares rose 2.9% to close at $12.96 on Friday.</li>\n <li>Raymond James lowered the price target on&nbsp;<b>Laredo Petroleum, Inc.</b>(NYSE:LPI) from $105 to $85. Laredo Petroleum shares climbed 2.5% to $56.79 in pre-market trading.</li>\n <li>Piper Sandler increased the price target for&nbsp;<b>Steven Madden, Ltd.</b>(NASDAQ:SHOO) from $54 to $56. Steven Madden shares rose 1.6% to $46.78 in pre-market trading.</li>\n <li>Credit Suisse lowered&nbsp;<b>Esperion Therapeutics, Inc.</b>(NASDAQ:ESPR) price target from $11 to $8. Esperion Therapeutics shares fell 0.6% to $5.22 in pre-market trading.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-06 21:31</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li>Cowen &amp; Co. raised the price target on&nbsp;<b>The Boston Beer Company, Inc.</b>(NYSE:SAM) from $400 to $500. Boston Beer shares rose 1% to $465.20 in pre-market trading.</li>\n <li>Keybanc lowered&nbsp;<b>Darden Restaurants, Inc.</b>(NYSE:DRI) price target from $180 to $172. Darden shares fell 0.5% to close at $142.35 on Friday.</li>\n <li>Barclays lifted&nbsp;<b>Ulta Beauty, Inc.</b>(NASDAQ:ULTA) price target from $492 to $516. Ulta Beauty shares rose 0.6% to $380.90 pre-market trading.</li>\n <li>Oppenheimer raised the price target on&nbsp;<b>Lowe's Companies, Inc.</b>(NYSE:LOW) from $235 to $300. Lowe's Companies shares rose 0.9% to $250.89 in pre-market trading.</li>\n <li>Telsey Advisory Group cut&nbsp;<b>Big Lots, Inc.</b>(NYSE:BIG) price target from $57 to $55. Big Lots shares rose 2.3% to $47.01 in pre-market trading.</li>\n <li>Morgan Stanley boosted the price target for&nbsp;<b>SVB Financial Group</b>(NASDAQ:SIVB) from $775 to $985. Morgan Stanley shares fell 5.3% to close at $674.57 on Friday.</li>\n <li>Goldman Sachs cut&nbsp;<b>Accel Entertainment, Inc.</b>(NYSE:ACEL) price target from $15.5 to $14.5. Accel Entertainment shares rose 2.9% to close at $12.96 on Friday.</li>\n <li>Raymond James lowered the price target on&nbsp;<b>Laredo Petroleum, Inc.</b>(NYSE:LPI) from $105 to $85. Laredo Petroleum shares climbed 2.5% to $56.79 in pre-market trading.</li>\n <li>Piper Sandler increased the price target for&nbsp;<b>Steven Madden, Ltd.</b>(NASDAQ:SHOO) from $54 to $56. Steven Madden shares rose 1.6% to $46.78 in pre-market trading.</li>\n <li>Credit Suisse lowered&nbsp;<b>Esperion Therapeutics, Inc.</b>(NASDAQ:ESPR) price target from $11 to $8. Esperion Therapeutics shares fell 0.6% to $5.22 in pre-market trading.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LOW":"劳氏","SHOO":"史蒂夫·马登","ACEL":"Accel Entertainment Inc","SAM":"波斯顿啤酒","ULTA":"Ulta美容","DRI":"达登饭店","BIG":"必乐透","ESPR":"Esperion Therapeutics Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163923112","content_text":"Cowen & Co. raised the price target on The Boston Beer Company, Inc.(NYSE:SAM) from $400 to $500. Boston Beer shares rose 1% to $465.20 in pre-market trading.\nKeybanc lowered Darden Restaurants, Inc.(NYSE:DRI) price target from $180 to $172. Darden shares fell 0.5% to close at $142.35 on Friday.\nBarclays lifted Ulta Beauty, Inc.(NASDAQ:ULTA) price target from $492 to $516. Ulta Beauty shares rose 0.6% to $380.90 pre-market trading.\nOppenheimer raised the price target on Lowe's Companies, Inc.(NYSE:LOW) from $235 to $300. Lowe's Companies shares rose 0.9% to $250.89 in pre-market trading.\nTelsey Advisory Group cut Big Lots, Inc.(NYSE:BIG) price target from $57 to $55. Big Lots shares rose 2.3% to $47.01 in pre-market trading.\nMorgan Stanley boosted the price target for SVB Financial Group(NASDAQ:SIVB) from $775 to $985. Morgan Stanley shares fell 5.3% to close at $674.57 on Friday.\nGoldman Sachs cut Accel Entertainment, Inc.(NYSE:ACEL) price target from $15.5 to $14.5. Accel Entertainment shares rose 2.9% to close at $12.96 on Friday.\nRaymond James lowered the price target on Laredo Petroleum, Inc.(NYSE:LPI) from $105 to $85. Laredo Petroleum shares climbed 2.5% to $56.79 in pre-market trading.\nPiper Sandler increased the price target for Steven Madden, Ltd.(NASDAQ:SHOO) from $54 to $56. Steven Madden shares rose 1.6% to $46.78 in pre-market trading.\nCredit Suisse lowered Esperion Therapeutics, Inc.(NASDAQ:ESPR) price target from $11 to $8. Esperion Therapeutics shares fell 0.6% to $5.22 in pre-market trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1053,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}